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Abstract 
 
Obesity, mainly central obesity (CO), is an inflammatory condition and represents a major 
threat to human health and lifespan. Assessment of health risk associated with excess 
adiposity requires, for one hand, an accurate measurement of obesity and for another hand 
identification of predictors of subclinical inflammatory obesity, which can be important 
tools for early therapeutic interventions in obesity-related comorbidities.  
The immunological-metabolic crosstalk regulates metabolism and immunity. It is not clear 
at present which neuroendocrine regulators or metabolic factors affect specifically the 
immune system in obesity. Sympathetic nervous system overactivity and a state of chronic 
immune activation are characteristics of obesity-related comorbidities. Catecholamines (CA) 
regulate both metabolism and immune response through activation of adrenergic (AR) and 
dopaminergic receptors (DR). Whether peripheral catecholaminergic system is involved in 
the low-grade inflammation linked to obesity is unknown. The migration of peripheral blood 
mononuclear cells (PBMC) towards sites of inflammation such as the adipose tissue is 
crucial to the development of sustained tissue inflammation. Circulating PBMC are exposed 
to systemic factors, such as dyslipidemia and inflammatory molecules and are directly 
involved in the low-grade chronic inflammation related to obesity. The expression of both 
AR and DR in immune cells under an obesogenic state is unknown. 
Herein, we aimed to identify subclinical inflammatory obesity predictors hypothesizing that 
body mass index (BMI) is less sensitive for early metabolic markers and inflammatory 
changes than waist circumference (WC) obesity-defined. We studied the catecholaminergic 
system in peripheral immune cells in inflammatory obesity, hypothesizing different 
expression pattern of catecholaminergic receptors with different metabolic outcomes 
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associations. For those purposes, a low-cardiovascular risk population was studied 
concerning anthropometric, metabolic, endocrine and inflammatory parameters. With a flow 
cytometry approach, we studied the signature of monocytes subsets. The expression of 
catecholaminergic receptors and tyrosine hydroxylase (TH), the rate-limiting step in CA 
synthesis, was assessed by real-time PCR in PBMC. Our study has the novelty of 
identification and prediction of subclinical inflammatory obesity contributing to: i) predict 
CO in more than one third with a model that includes the determination of plasma levels of 
leptin and very low-density lipoprotein-cholesterol (VLDL-C) and CD14 expression in 
monocytes subsets; ii) suggest that in subclinical inflammatory obesity, dyslipidemia and 
leptin induce monocytes maturation process rather than an independent arise of CD16+ 
monocytes; iii) suggest CA immunomodulation in obesity; iv) explain the stronger 
association of CO measures with cardiometabolic risk in comparison with general obesity 
assessed by BMI and v) recommend, in a public health setting, the implementation of WC as 
a priority tool for inflammatory obesity screening in low cardiovascular risk population. 
Focused on the expression of AR in immune cells, we performed a pilot study considering 
PBMC expression of all the 9 AR (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2 and β3) in a subgroup of 
subjects with and without CO. The preliminary results revealed that there were no 
differences between groups except for β2AR mRNA levels. This finding led us to study 
β2AR expression in whole population showing that β2AR in PBMC were under expressed in 
CO individuals in comparison to no-CO subjects. The multiple logistic regression analysis 
showed a lower and higher association, respectively for β2AR expression and female gender 
for the occurrence of CO. PBMC from subjects with CO showed a reduction of the 
expression of DR D2, DR D4 and DR D5 as well as lower levels of TH mRNA in 
comparison to cells from the non-obese group. Logistic regression analysis revealed that DR 
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D2 expression may have a protective role for the existence of CO. β2AR expression inversely 
correlated with plasma triacylglycerol (TAG), VLDL-C and leptin and positively with HDL-
C plasma levels. CO individuals showed higher TC, VLDL–C and leptin plasma levels and a 
higher inflammatory pattern of monocytes relatively to no-CO subjects. AD and NA plasma 
levels were associated with dyslipidemia. In addition, our work suggests an inflammatory 
role for NA supported by the association of its plasma values with “pro-inflammatory 
monocytes” number and with hsCRP levels. DR D2 and DR D5 expression in PBMC 
strongly correlates with lower weight, BMI and WC, lower plasma levels of leptin and with 
a lower inflammatory pattern, while DR D4 mRNA correlates with less HbA1c and TH 
mRNA correlates with lower WC and leptin levels. 
In conclusion, we identified predictors of subclinical inflammatory obesity, the expression 
of catecholaminergic receptors in PBMC has a different pattern in inflammatory obesity and 
associate with a better metabolic profile and with a lower inflammatory state. 
The findings of a predictor model and the protective role of β2AR and DR D2 expression in 
peripheral immune cells for inflammatory obesity are expected to impact, first, on early 
diagnosis with implementation of WC measurement at primary care settings to define 
obesity and secondly, on therapeutic interventions in inflammatory obesity. 
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Resumo 
 
A obesidade, sobretudo a obesidade central (OC), é uma condição inflamatória e representa 
uma ameaça para a saúde e longevidade humanas. A avaliação do risco para a saúde 
associado ao excesso de adiposidade exige, por um lado, uma medição precisa e, por outro 
lado, a identificação de preditores da obesidade inflamatória subclínica. Estes podem 
representar ferramentas importantes para as intervenções terapêuticas precoces nas co-
morbilidades da obesidade.  
A interligação entre metabolismo e imunidade regula a resposta metabólica e a resposta 
imunológica. Contudo, ainda são desconhecidos os reguladores neuroendócrinos ou os 
fatores metabólicos que afetam especificamente o sistema imunológico na obesidade. A 
obesidade e as suas co-morbilidades caracterizam-se por apresentarem aumento da atividade 
do Sistema Nervoso Simpático e ativação crónica do sistema imunitário. As catecolaminas 
(CA) regulam o metabolismo e a resposta imunológica através da sua ligação aos recetores 
adrenérgicos (RA) e dopaminérgicos (RD). Desconhece-se se o sistema catecolaminérgico 
periférico está envolvido na inflamação crónica de baixo grau associada à obesidade. A 
migração das células mononucleares do sangue periférico (PBMC) para os locais de 
inflamação, como o tecido adiposo, é crucial para o aparecimento e cronicidade da 
inflamação associada à obesidade. As PBMC, expostas a fatores sistémicos como a 
dislipidemia e moléculas inflamatórias, estão diretamente envolvidas na inflamação da 
obesidade. Porém, a expressão dos RA e RD nas células imunológicas no estado 
obesogénico é desconhecida. 
Assim, o objetivo inicial foi a identificação de preditores da obesidade inflamatória 
subclínica, colocando a hipótese de que o perímetro abdominal (PA) é mais sensível que o 
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índice de massa corporal (IMC) para marcadores metabólicos e alterações inflamatórias das 
PBMC na obesidade. Estudámos o sistema catecolaminérgico nas células imunitárias 
periféricas na obesidade inflamatória, tendo como hipótese a existência de um padrão 
diferente de expressão dos recetores das CA com associação a diferentes consequências 
metabólicas. 
Com esta finalidade, uma população de baixo risco cardiovascular foi estudada 
relativamente a parâmetros antropométricos, metabólicos, endócrinos e inflamatórios. Por 
citometria de fluxo analisámos a assinatura imunofenotípica das subpopulações de 
monócitos. A expressão dos recetores catecolaminérgicos e da hidroxilase de tirosina (TH), 
a enzima limitante da taxa de síntese das CA, foi avaliada por PCR em tempo real nas 
PBMC. O nosso estudo tem a novidade de identificação e predição de obesidade 
inflamatória subclínica contribuindo para: i) prever OC em mais de um terço com um 
modelo que inclui a determinação dos níveis plasmáticos de leptina e de very low-density 
lipoprotein- colesterol (VLDL-C) e a expressão de CD14 nas subpopulações de monócitos; 
ii) sugerir que na obesidade inflamatória subclínica, a dislipidemia e a leptina induzem um 
processo de maturação nos monócitos em vez da expansão do número de monócitos CD16 
+; iii) sugerir imunomodulação pelas CA na obesidade; iv) explicar a maior associação da 
OC com risco cardiometabólico em comparação com a obesidade geral avaliada pelo IMC e 
v) recomendar, em saúde pública, a implementação do PA como um instrumento prioritário 
para o rastreio da obesidade inflamatória nas populações de baixo risco cardiovascular. 
Tendo em conta a expressão de RA nas células do sistema imunológico, realizamos um 
estudo piloto nas PBMC relativamente à expressão de todos os 9 RA (α1A, α1B, α1D, α2A, 
α2B, α2C, β1, β2 e β3) num subgrupo de indivíduos com e sem OC. Os resultados 
preliminares não revelaram diferenças entre os grupos exceto para os níveis de ARNm dos 
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RA β2. Estes dados levaram-nos a estudar a expressão dos RA β2 em todos os indivíduos 
mostrando que os RA β2 estavam sub-expressos nas PBMC nos indivíduos com OC 
comparativamente aos indivíduos sem OC. A análise de regressão logística múltipla mostrou 
uma associação menor e maior entre a existência de OC e, respetivamente, a expressão dos 
RA β2 e o sexo feminino. As PBMC de indivíduos com OC mostraram uma redução da 
expressão dos RD D2, RD D4 e RD D5, bem como níveis mais baixos dos transcritos da TH 
em comparação com as células do grupo sem OC. A análise de regressão logística revelou 
que a expressão do RD D2 pode ter um papel protetor para a existência da obesidade central. 
A expressão dos RA β2 correlacionou-se inversamente com os níveis plasmáticos de 
triacilglicerol, VLDL-C e leptina e positivamente com os níveis plasmáticos de high-density 
lipoprotein- colesterol (HDL-C). Os indivíduos com OC apresentaram valores plasmáticos 
mais elevados de colesterol total, VLDL-C e de leptina e monócitos com um padrão mais 
inflamatório relativamente aos indivíduos sem OC. Os níveis plasmáticos de adrenalina 
(AD) e de noradrenalina (NA) mostraram associação com a dislipidemia. Além disso, o 
nosso trabalho sugere um papel inflamatório para a NA suportado pela associação dos seus 
valores no plasma com o número de "monócitos pró-inflamatórios" e com os níveis de 
proteína C reativa de alta sensibilidade. A expressão dos RD D2 e RD D5 nas PBMC 
correlacionam-se fortemente com menor peso, IMC e PA, menores níveis plasmáticos de 
leptina e com um padrão inflamatório mais baixo. A expressão do RD D4 correlaciona-se 
com valores mais baixos da hemoglobina glicosilada e o ARNm da TH correlaciona-se com 
níveis mais baixos do PA e da leptina. 
Em conclusão, foram identificados preditores de obesidade inflamatória subclínica, a 
expressão dos recetores catecolaminérgicos nas PBMC tem um padrão diferente na 
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obesidade inflamatória e associa-se a um melhor perfil metabólico e a um estado 
inflamatório mais baixo. 
Os resultados de um modelo preditor e o papel protetor da expressão do RA β2 e do RD D2 
nas células imunológicas periféricas para a obesidade inflamatória apresentam 
potencialmente impacto, em primeiro lugar, no diagnóstico precoce com a implementação 
da medida do PA para definir obesidade nos cuidados de saúde primários e, em segundo 
lugar, nas intervenções terapêuticas precoces na obesidade inflamatória. 
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Chapter 1: Introduction 
1.1 Humanity on the fat track 
Humanity is getting fat and this trend appears to be continuing (1). We are facing a 
worldwide obesity epidemic, independently of gender, age, economic status, race or 
ethnicity that shows little sign of slowing (1). Obesity is associated with an increased risk of 
insulin resistance, type 2 diabetes (T2D), fatty liver disease, dyslipidemia, 
neurodegenerative disorders, including dementia, airway disease, certain types of cancers (2) 
and with premature death (3) (Figure 1). Because the extent of the increase in the obesity 
prevalence over the last 25 years was not predictable from the obesity prevalence data prior 
to 1980 (4), the term “obesity epidemic” is used with the meaning of a “rapid spread” 
instead of as a communicable disease. 
Worldwide, the proportion of overweight/obese adults (body mass index, BMI ≥ 25 kg.m-²) 
increased between 1980 and 2013 from 28.8% to 36·9% in men, and from 29.8% to 38.0% 
in women. In developing countries with emerging economies, the rate of increase of 
childhood overweight and obesity has been more than 30% higher than that of developed 
countries (5).  
In 2014, more than 1.9 billion adults were overweight and of these over 600 million were 
obese. Overall, about 13% of the world’s adult population (11% of men and 15% of women) 
was obese. 
Overweight and obesity are linked to more deaths worldwide than underweight (5). 
Consequently, with the shift in the population age structure to older demographics, the 
burden of obesity and its associated comorbidities are expected to shrink the healthy lifespan 
(6, 7). 
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The rapidity with which the incidence of obesity has increased worldwide is unlikely 
explained by genetic changes. Human obesity is due to a mismatch between adaptive 
biological characteristics of our species and the modern environment, which has changed 
dramatically from the one that we evolved. In evolution, selective pressures do not favor the 
development of countermeasures against excess nutrients and energy, but rather select for 
phenotypes that ensure survival in the face of deficiencies. In a physiological perspective, 
food intake is regulated by internal mechanisms defending homeostasis. Multiple factors 
contribute to obesity, including but not limited to genetic, dietary, economic, psychosocial, 
reproductive, and pharmacological factors. The main negative features of contemporary 
lifestyle include stress (long-term and continuous, psychological), positive energy balance 
(excessive energy intake and low physical activity, called “the big two”), low-quality food 
(both high fat and energy dense, and at the same time poor in micronutrients), and disruption 
of chronobiology (9). While the cause of this epidemic remains unclear, obesity can be 
conceived as a failure of total body energy homeostasis. Most energy stores are in the form 
of lipids stored in adipose tissue, so the homeostatic model define obesity as failure of 
lipostatic mechanisms, and thus considered as pathology. 
Figure 1 Immunometabolic impact on health. Chronic metabolic inflammation, metaflammation, in multiple 
organs is implicated in metabolic disease. In metabolic organs including the liver, brain, pancreas and adipose 
tissue, inflammatory cell action and interactions within the stromal components is an important determinant of 
maintenance of tissue homeostasis as well as metabolic disease pathogenesis. Owing to their proximity, 
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immune cells may sense and react to changes in nutrient availability, and in turn influence the intrinsic 
metabolic action within neighboring cells critical for metabolic homeostasis, for example by altering lipid 
metabolism or inhibiting glucose uptake. These tissues and mediators produced from them also cause systemic 
inflammatory responses and disrupt metabolic homeostasis. As a result, immunometabolic diseases often 
emerge as clusters and promote ageing, disability and premature death. Copyright with License Number 
4073871408191 from Nature Publishing Group of the manuscript Gökhan S. Hotamisligil. Nature (2017) 
542:177–185 . 
 
1.2 Yin and yang of measuring obesity: Disease and obesity paradox 
In 2013, the American Medical Association classified obesity as a disease (10). Assessment 
of health risk associated with excess adiposity requires, for one hand, an accurate 
measurement of obesity and for another hand the identification of early markers of adult 
obesity in order to prevent its comorbidities. Finding sensitive tools towards the 
identification of obesity inflammatory conditions is a challenging assignment. 
Traditionally, obesity is defined based on the BMI as equal to or greater than 30 kg.m-² 
according to the World Health Organization (WHO) (11). Waist circumference (WC) greater 
than 0.94 m for men and 0.80 m for women (11) in Caucasians, defining central obesity 
(CO) is an alternative anthropometric index of obesity. Despite the well-documented 
association between visceral adipose tissue (VAT) and cardiometabolic risk (CMR), there is 
discordance between BMI and WC driven by the substantial variability in VAT for a given 
BMI. Waist circumference was associated with VAT, liver fat, and CMR factors (12). 
Indeed, BMI neither indicates fat distribution nor does distinguish fat mass from fat-free 
mass, which have opposite associations with health risk (13). In addition, the validity of 
BMI as a marker of fatness in elderly persons is limited because fat-free mass decreases with 
aging, even without a change in overall weight (14). In contrast, WC is highly correlated 
with visceral fat measured by computed tomography (15), and better estimates obesity-
associated cardiovascular risk in comparison to BMI (12). 
More sensitive indicators than BMI, like body adiposity and its distribution, should be 
projected on mortality to yield more accurate associations with an increased health risk.  
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The observation that overweight and even obese patients might be protected against adverse 
cardiovascular events has generated the term ‘metabolically healthy obesity (MHO)’, to 
describe the absence of components of the metabolic syndrome (hypertension, dyslipidemia, 
high fasting glucose levels and T2D) in the presence of an increased BMI (13). However, 
there are no MHO criteria definition and many authors have questioned the existence and 
benign nature of such an entity, because MHO definition criteria are not consistent across 
the literature (14). Most of the studies have incomplete information on key confounding 
variables, including CO. Obese patients often transit from a healthy to an unhealthy 
phenotype (15) and studies with follow-up periods longer than 10 years demonstrate no 
benefit – or even an increased risk for cardiovascular events – compared with metabolically 
healthy normal weight individuals (16, 17). This paradox underlines the importance of an 
accurate measurement of obesity and the identification of its early pathological markers in 
order to promote early therapeutic interventions to prevent comorbidities obesity-associated 
including premature death. 
 
1.3 Obesity is an inflammatory systemic disease 
It is widely accepted that chronic systemic low-grade inflammation is associated with the 
development of obesity and metabolic dysfunction. Compared with lean tissue, obese 
adipose tissue (AT) secretes inflammatory cytokines inhibiting insulin signaling (18). This 
observation contributed to the concept of the link between inflammatory and metabolic 
responses, and the research field of immune cells- adipocytes crosstalk gave rise to the term 
“immunometabolism” (19). These studies first demonstrated the common pathways of 
immune and metabolic systems and the detrimental effects that this crosstalk can have on 
cellular and systemic metabolism.  
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The hallmarks of obesity-induced inflammation have been described as different from the 
Celsius paradigm. In obese state, inflammation is moderate-low-grade and local expression 
of inflammatory mediators induced by stress sensors triggered by metabolic signal, a 
nutrient-induced inflammatory response is orchestrated by adipocytes. These metabolic cells 
create a modified milieu with altered composition of immune cells favoring a 
proinflammatory tissue environment. This chronic maintenance of the inflammatory state 
without apparent resolution is, unlike the classic paradigm, associated with a reduced 
metabolic rate (20). In contrast Asterholm et al. (2014) (21) suggest that AT inflammation is 
an adaptive response that enables safe storage of excess nutrients and contributes to a 
visceral depot barrier that effectively filters gut-derived endotoxin. Upon high fat diet (HFD) 
exposure, the expansion of VAT is associated with decreased intestinal barrier function, 
increased hepatic steatosis and metabolic dysfunction. An impaired local pro-inflammatory 
response in the adipocyte leads to increased ectopic lipid accumulation, glucose intolerance 
and systemic inflammation.  
The precise temporal sequence of inflammatory cell infiltration into AT is still unclear. 
Similarly, it is unknown the initiating events that link overnutrition to inflammation. 
The systemic effects of obesity are linked to an imbalance in homeostatic and 
proinflammatory immune responses. Obesity triggers inflammatory pathways in the brain 
and in AT dysregulating physiological responses that maintain insulin and leptin sensitivity. 
Independent of obesity, hypothalamic inflammation can impair insulin release from β cells, 
impair peripheral insulin action and potentiate hypertension. The sympathetic nervous 
system (SNS) originates most of these effects being able, as well, to induce inflammatory 
changes in AT in response to neuronal injury (22). Over time, ectopic lipid accumulation in 
muscle, liver, and blood vessels activates tissue leukocytes, contributes to organ-specific 
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disease, and exacerbates systemic insulin resistance. Cellular- and cytokine-mediated 
inflammation in pancreatic islets accelerates the progression toward diabetes. With HFD, 
metabolites such as diacylglycerols and ceramides accumulate in the hypothalamus and 
induce leptin and insulin resistance in the central nervous system (CNS) (23, 24). Saturated 
fatty acids, which activate neuronal c-Jun N-terminal protein kinases (JNK) and nuclear 
factor-κB (NF-κB) signaling pathways with direct effects on leptin and insulin signaling 
mediate part of this effect (25).  
Visceral adiposity is predictive of T2D, cardiovascular disease and hepatic steatosis, 
whereas subcutaneous fat increase does not show, clearly, association to a higher risk of 
these conditions (21). Visceral and subcutaneous AT differ in immune cell composition, 
particularly macrophages. Increased macrophage accumulation has been demonstrated in AT 
of humans with obesity and/or with T2D, with significantly more macrophages in visceral 
fat depot compared to subcutaneous depot (21). Increased macrophage accumulation in VAT 
may be a key pathologic feature of obesity and its comorbidities mentioned before. 
Dysfunctional AT is central to obesity and associated disorders. In addition to a matrix of 
extracellular proteins, adipocytes are surrounded by a variety of cells including immune 
cells, endothelium, fibroblasts, preadipocytes, and stem cells. Mature lipid-laden adipocytes 
represent 20%–40% of the cellular content of a fat pad; every gram of AT contains 1–2 
million adipocytes but 4–6 million stromal-vascular cells, of which more than half are 
leukocytes (26). Adipose tissue is an important source of tumor necrosis factor α (TNF-α) 
and other cytokines, being their production magnified by overnutrition (18, 27). Many of 
these cytokines are produced by macrophages within the fat pad rather than the adipocytes 
themselves (28, 29). These macrophages can be observed histologically as ‘‘crown-like 
structures’’ surrounding adipocytes, particularly in obese visceral fat; their distribution has 
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been attributed to clustering around dead or dying adipocytes (30). Phenotypically, 
macrophages exist along a spectrum, the poles of which have been designated M1 
(‘‘classically activated’’) and M2 (‘‘alternatively activated’’). M1 macrophages have a 
proinflammatory phenotype expressing cytokines like TNF-α, interleukin 6 (IL-6), and IL-
1β in response to lipopolysaccharide (LPS) and interferon  (IFN-). M2 macrophages, on 
the other hand, play a role in tissue remodeling and wound healing and secret anti-
inflammatory cytokines like IL-10 and IL-1 receptor antagonist. As obesity progresses, more 
M1 macrophages infiltrate the fat pad, causing insulin resistance (31). Adipose M2 
macrophage numbers do not diminish in obesity and may even increase; but there is a major 
shift in the M1/M2 ratio favoring a proinflammatory state (32). 
Virtually all known classes of immune cell have been implicated in setting the inflammatory 
environment in AT. During obesity, the expansion of effector T cells population and 
recruitment of AT macrophages is paralleled by an increase in the number of B-2 cells with 
no change in the frequency of B-1a cells (33, 34). Inflammatory T cells (T helper type 1 
cells and cytotoxic CD8+ T cells) contribute to metabolic dysfunction by producing potent 
M1 macrophage–inducing cytokines, including IFN-δ, TNF-α and IL-6. Lean AT shows 
considerable enrichment for regulatory T cells (Treg cells) that express the transcription 
factor Foxp3, and these cells have been suggested to dampen proinflammatory responses 
and the recruitment of M1 macrophages through the release of IL-10 and transforming 
growth factor-β (26).  
Adipocyte ‘‘stress’’ due to overnutrition has been linked to oxidative stress, endoplasmic 
reticulum stress, and toll-like receptors (TLRs) activation due to fatty acids and/or bacterial 
LPS (metabolic endotoxemia) which may be elevated in the serum of obese subjects (35-37). 
These insults cause upregulation of various chemokines in adipocytes, which recruit immune 
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cells to the fat pad. These chemokines include monocyte chemotactic protein 1 (MCP-1) 
among others. A recent study suggests that adipocytes may act as the antigen-presenting 
cells (APCs) that activate resident T cells shortly after the initiation of HFD (38), though 
others suggest that AT macrophages (ATM) are the relevant APCs (39).  
An intriguing example of adipose-macrophage crosstalk is the newly discovered role of M2 
macrophages to promote browning of white AT. Cold exposure was found to polarize 
macrophages toward the alternatively activated form in an IL-4-dependent manner, leading 
to the formation and secretion of catecholamines (CA) (40). 
As stated before, cells of the immune system chiefly contribute to the persistent state of 
inflammation responsible for metabolic dysfunction during obesity but the identity of the 
specific immune receptors that sense metabolic-stress signals and trigger inflammation 
remain largely unknown. Recruitment of macrophages into AT is an early event in obesity-
induced adipose inflammation (31). Tissue macrophages are derived from circulating 
monocytes, and the infiltration of monocytes into tissues is a complex phenomenon with 
increased expression of adhesion molecules, transmigration of monocytes across the 
endothelium, migration along a chemotactic gradient into underlying tissues, and, finally, 
differentiation of monocytes into tissue macrophages (31).  
 
1.4 Monocyte subsets reveal another link between systemic inflammation 
and obesity 
Monocytes originate in bone marrow and are released into peripheral blood, where they 
circulate for several days. They are part of the mononuclear-phagocyte system, including 
macrophages, dendritic cells, and their bone-marrow precursors. Monocytes represent 5–
10% of peripheral leucocytes serving as a systemic reservoir of myeloid precursors that are 
45 
 
needed for the renewal of tissue macrophages and dendritic cells. However, they also have 
other well-documented functions in immune response against infection (41) and in 
pathogenesis of several inflammatory disorders, including obesity and atherosclerosis (42). 
Although initially perceived as a homogeneous population, it has become increasingly 
apparent that monocytes display considerable heterogeneity with respect to their phenotype 
and function (43, 44).  
Two major subsets have been described for monocytes, according to their 
immunophenotype: classical CD14+CD16- (CD16-) and non-classical, CD14+CD16+ 
(CD16+) subsets (41). CD16- and CD16+ monocytes are also differentiated by respectively 
higher and lower expression of both CD36 and CD11b (44). CD16-positive monocytes were 
first described as a single subpopulation (43) that, compared with CD16-negative 
monocytes, were smaller, had somewhat diminished expression of CD14, contained fewer 
cytosolic granules, and exhibited a lower rate of phagocytosis (43). CD16+ monocytes are 
considered “proinflammatory” cells since they exhibit a macrophage-like phenotype with 
enhanced antigen-presenting capacities, higher endothelial affinity and production of 
proinflammatory cytokines (44). Accordingly, CD16+ monocytes expansion has been 
described in inflammatory states, such as sepsis, rheumatoid arthritis, infections (41) and in 
patients with a high cardiovascular mortality risk (45, 46).  
In humans, over the years, monocytes have been divided into three subtypes based on 
relative surface expression of LPS co-receptor CD14 and FCγIII receptor CD16 (44) that 
binds IgG complexed with modified low-density lipoprotein (LDL) cholesterol (47). The 
most predominant of the three, termed “classical monocytes”, do express high levels of 
CD14 on their surface, are devoid of surface CD16, and account for approximately 80% of 
the total monocyte population. The remaining 20% express CD16 and they have been further 
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classified into two subtypes. The more abundant “nonclassical monocytes”, are 
characterized by very low expression of surface CD14 and high levels of CD16, whereas the 
third monocyte subtype, called “intermediate monocytes”, express intermediate levels of 
both the receptors (44). As stated before, CD16+ monocytes are phenotypically 
heterogeneous, expressing a different set of chemokine receptors and adhesion molecules, 
and therefore have different homing characteristics and functional properties than CD16-
negative monocytes (48). The greater chemokine receptor expression and enhanced in vitro 
migratory capacity strongly infer that the increase in macrophages in the AT of humans with 
obesity results, partially, from recruitment of new cells into the tissue. Krinninger et al. 
(2014) (49) demonstrated that monocytes, the circulating precursors of macrophages, from 
obese women show increased chemokine receptor expression comparatively to lean women 
and that these differences could promote accumulation of proinflammatory macrophages in 
AT. 
Based on this original classification scheme, CD16-positive monocytes were associated with 
cardiovascular disease. Patients with coronary artery disease exhibited higher circulating 
numbers of CD16-positive monocytes than healthy controls (50), and those in the highest 
quartile for circulating CD16-positive monocytes also had significantly higher serum TNF-α 
concentrations.  
Over the years, several studies, often contradictory, aimed at functional characterization of 
the monocyte subsets have been undertaken by different research groups (51, 52). Two main 
reasons have been pointed out: lack of a standardized gating strategy for 
immunophenotyping by flow cytometry and functional studies have been performed with 
purified monocytes, contributing to highly variable results depending on method of isolation 
employed (53). ‘Classical’ monocytes are phagocytic with no inflammatory characteristics, 
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‘non-classical’ subtype display ‘inflammatory’ characteristics on activation and exhibit 
properties for antigen presentation while ‘intermediate’ monocytes constitute a very small 
percentage in circulation and appear to be a minor transitional subset that displays both 
phagocytic and inflammatory function (53) (Figure 2). Mukherjee et al. (2015) (53) 
demonstrated unequivocally that nonclassical (but not intermediate) monocytes are the 
primary inflammatory monocytes and further validate by studying patients with acute and 
chronic inflammatory diseases. However, the temporal relationship of the change in 
monocyte phenotype with respect to development of obesity remains to be investigated. The 
pathophysiological significance of monocytes subsets fluctuations both in number and 
phenotypic pattern in inflammatory diseases is unknown. Moreover, in inflammatory 
obesity, it is uncertain whether there is an expansion of CD16+ cells or a maturation process 
from classical to non-classical monocytes and if CA, important immunomodulators 
(developed in item 1.6), are associated with monocytes characteristics observed in that 
condition. 
 
Figure 2 Representative example of monocyte subsets: whole blood protocol; monocyte scatter properties 
were gated and monocyte subpopulations were defined according to their surface expression pattern of the LPS 
receptor CD14 and the Fcδ receptor CD16. CD16- and CD16+ monocytes are also differentiated by 
respectively higher and lower expression of both CD36 and CD11b. Monocytes subsets are a continuum cell 
population. 
 
Non-classical monocytes CD14+low CD16+high 
Classical monocytes CD14+high CD16-/+low 
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1.5 Pathways of adipocytes-immune cells crosstalk 
1.5.1 Leptin immunomodulation  
The discovery of leptin brought the concept of adipocytes as active endocrine cells, 
identifying a specific biological cause of obesity (at least in mice), and subsequent target for 
a rational drug therapy. Though small amounts may be produced by other tissues in specific 
contexts (54), the main source of leptin comes from adipocytes, and serum levels are 
associated with fat mass (55). Many factors regulate leptin expression and secretion, 
including nutrients, steroid and thyroid hormones, and cytokines (54).  
The adipokine leptin is the product of the obese gene (ob; also, known as Lep), regulating 
feeding behavior through the CNS. Functionally, leptin affects the hypothalamus region of 
the brain, where it triggers satiety signals, regulates food intake by counter-acting ghrelin, 
the hunger hormone, but also promotes energy expenditure in peripheral tissues (56). 
Chronically high leptin levels can lead to leptin resistance and changes in the dynamics of 
fat storage, glucose metabolism and insulin signaling. However, the leptin receptor is 
expressed not only in the CNS, but also in peripheral tissues, such as hematopoietic and 
immune systems (57). Leptin receptor is expressed in human PBMC, namely in monocytes 
(58), mediating the leptin effect on proliferation and activation. Leptin shares structural 
similarity with IL-6 and acts on immune cells via the leptin receptor, which belongs to the 
cytokine receptor family. Stimulation of the leptin receptor activates Janus kinase- Signal 
Transducer and activation of transcription (JAK–STAT), insulin receptor substrate 1- 
phosphoinositide 3 kinase (IRS-1-PI3K) and mitogen-activated protein kinases (MAPK) 
signaling pathways, and it has been suggested that it modulates RNA metabolism (59). 
Because it shares a similar signal transduction mechanism as cytokines, leptin signaling can 
promote obesity-associated induction of pro-inflammatory mediators (60). Therefore, the 
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physiological role of leptin should not be limited to the regulation of food intake and energy 
expenditure. In addition, leptin stimulates the production of proinflammatory cytokines from 
cultured monocytes and enhances the production of Th1 type cytokines from stimulated 
lymphocytes. Moreover, leptin has a trophic effect on monocytes, preventing apoptosis 
induced by serum deprivation. These signal transduction pathways provide possible 
mechanisms whereby leptin may modulate activation of PBMC. Moreover, Cannon et al. 
(2014) (61) showed evidence that leptin promotes CD16 expression on human monocytes 
being a critical link between adiposity and inflammation.  
Deficiency of leptin receptor led to decreased AT infiltration of inflammatory macrophages 
and to decreased expression of pro-inflammatory cytokines in AT. Therefore, leptin can be 
regarded as a proinflammatory cytokine with major role in the link between the nutritional 
status and the immune response with importance in the pathophysiology of obesity (62).  
Contrary to its pro-inflammatory effects, leptin can also reduce AT inflammation by 
enabling a leptin-catecholamine signaling axis (63). Over-nutrition triggers leptin-mediated 
increases in sympathetic nerve activity that stimulate the mobilization of triglycerides from 
AT. Administration of exogenous leptin increased expression of noradrenaline in AT, which 
increased cyclic adenosine monophosphate (cAMP) production, ultimately leading to 
dephosphorization and nuclear translocation of a histone deacetylase that can inhibit NF-κB-
mediated inflammation, dephosphorization, nuclear translocation, and association with 
genes that transcribe proinflammatory cytokines, namely TNFα and IL-12. Increased 
expression of pro-inflammatory cytokines in macrophages, as well as increased crown-like 
structure formation in AT contribute to metabolic dysfunction (64).  
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1.5.2 The nutritional mechanism in the link between immune and metabolic systems 
Obesity is a chronic low-grade inflammatory condition promoted by hyperlipidemia 
involving cells of the innate and adaptive immune system. Moreover, the immune system 
affects lipids and lipoprotein levels and cellular lipid homeostasis can influence the level and 
function of immune cells (65). 
Lipoproteins provide hydrophilic properties to lipids, allowing them to be transported within 
aqueous environments inside and outside of cells. Some well-studied lipoproteins include 
Apolipoprotein (Apo) A and E that bind lipids reversibly to form high density lipoprotein 
(HDL) and Apo B that binds lipids irreversibly to form LDL. One of the main functions of 
HDL is to promote cholesterol efflux from cells. As such, decreased HDL levels are 
indicative of increased atherosclerosis and cardiovascular events (64). 
The fat molecule transporter HDL has anti-inflammatory properties including decreasing 
expression of adhesion molecules, TNF and chemokine (C-C motif) ligand (CCL2) in 
endothelial cells. LDL is also a fat molecule transporter; it differs from HDL in that it 
contains higher proportions of fat molecules. In conditions of oxidative stress, LDL is 
susceptible to oxidation, and can form aggregates. These oxidized LDL (oxLDL) aggregates 
form fat droplets that are recognized by scavenger receptors on monocytes/macrophages, 
such CD36, and lead to macrophage development into foam cells precipitating 
atherosclerotic events. Moreover, oxLDL, as well as cholesterol, cause dysfunction in 
macrophage lysosomal activity that contributes to processing of lipids (66).  
Considering nutritional mechanisms, adipocytes safely store excess calories during periods 
of nutritional affluence and release them when there is nutritional deprivation. These 
calories come in the form of free fatty acids (FFA), which are liberated by lipolysis during 
fasting and are released into the circulation, where they are utilized by skeletal muscle and 
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other tissues. By enabling these tissues to switch to a lipid-oxidizing economy during 
fasting, glucose is spared for the CNS and red blood cells. This is usually achieved through 
the coordinated action of hormones, CA and insulin being the chief regulators of this 
balance (65). 
Free fatty acids or, also named, non-esterified fatty acids (NEFAs) are chronically elevated 
in the circulation of obese subjects (67), activating intracellular inflammatory signaling 
pathways. An increase in concentration of circulating NEFA reflects the inability of the AT 
to buffer the excess nutrient intake and is related to the dyslipidemic state that characterizes 
obesity. When overload becomes present, the liver increases the production of apo-B 
containing particles that carry triacylglycerol to the AT resulting in low-density lipoprotein 
(LDL) formation (68). This occurs in VAT very efficiently and this depot is also more 
capable of releasing lipids in times of requirement. When the capacity of storing fat in AT is 
overwhelmed, the conversion of very low-density lipoprotein (VLDL) is delayed originating 
hypertriglyceridemia (69). Individuals with insulin resistance have increased secretion rates 
of VLDL-apoB and triglycerides. In obesity, the main regulators of abnormal apoB and 
triglyceride kinetics are visceral fat, hepatic fat, insulin resistance and plasma adiponectin. 
An increased amount of peritoneal fat results in an alteration of portal FFA flux, an altered 
pattern of adipocytokines and a disturbed ratio of proinflammatory to anti-inflammatory 
processes. Free fatty acids, adipocytokines and inflammation affect each other, being 
intimately linked. Although each factor may increase VLDL secretion by itself, it is the 
altered flow of FFA that probably has the greatest impact on driving hepatic VLDL 
overproduction (68). Furthermore, not fat store tissues such as liver, muscle and pancreas 
accumulate lipids (69), and the resulting lipotoxicity may induce insulin resistance. 
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Though most of the lipid stored in adipocytes comes from the diet, the fat cell is fully 
capable of synthesizing new lipids from carbohydrates using de novo lipogenesis. Lipolysis 
is the process that is required for fatty acids to be liberated from triglyceride so that they can 
be oxidized locally or by other organs. Classically, lipolysis is accepted as being driven by 
β-adrenergic signaling in the adipocyte, but other inducers (such as TNF-α) exist and may 
have physiological relevance (70).  
Adipocytes are involved in innate immunity, expressing toll-like receptors (TLRs) in these 
cells. The two most widely studied TLRs are TLR2 and TLR4, which are activated by 
bacterial lipoproteins and by LPS, respectively. The engagement of either receptor leads to 
translocation of nuclear factor κB (NFκB) to the nucleus. In addition to their early 
recognized role in immunity, a participation in the regulation of metabolism is also being 
attributed to TLRs (70). Saturated fatty acids activate both TLR2 and TLR4 and, instead, 
unsaturated fatty acids inhibit TLR-mediated signaling and gene expression. Activation of 
TLRs results in synthesis of proinflammatory factors such as TNF-α, IL-6, and chemokines 
(74).  
Lipid species appear to regulate inflammatory signaling in macrophages through non-TLR 
pathways as well. Overexpression of diacylglycerol transferase-1 (DGAT-1, which catalyzes 
the final stage in triglyceride synthesis) in macrophages protects against adipose 
macrophage infiltration, inflammation and insulin resistance (71). Diacylglycerols have been 
implicated in insulin resistance in liver and muscle (71). In addition, ceramides have 
recently been shown to activate the nucleotide-binding domain, leucine-rich-containing 
family, and pyrin-domain-containing (NLRP) inflammasome (72). NLRP activation 
ultimately leads to IL-1𝛽 and IL-18 secretion, a response that is generally stimulated by 
“danger signals” of non-microbial origin. Omega-3 fatty acids have anti-inflammatory and 
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antidiabetic effects in humans and mice. Activation of the omega-3 fatty acid receptor, G 
protein coupled receptor 120 (GPCR120), on macrophages and adipocytes reverses adipose 
inflammation and insulin resistance in obese mice (73). 
 
1.5.3 Catecholaminergic regulation of metabolism and Obesity 
The CA, adrenaline (AD) and noradrenaline (NA) are considered the major regulators of 
lipolysis (74) affecting differentiation and proliferation of adipocytes. Impairment of CA-
induced lipolysis in adipocytes is thought to contribute to the development of obesity 
characterized by adrenergic over activity (74, 75). 
In terms of metabolism, the SNS is fundamental in controlling daily energy expenditure via 
the regulation of resting metabolic rate and initiation of thermogenesis in response to 
physiological stimuli, such as, changing energy states, food intake, carbohydrate 
consumption, hyperinsulinemia, and exposure to cold. Sympathetic tone is an important 
mediator of cardiovascular function predominantly through its direct effects on β-adrenergic 
receptors in the heart to modulate cardiac output and on α-adrenergic receptors (α-AR) in 
blood vessels to modulate arteriolar resistance and venous capacitance. Activation of 
sympathetic nerves innervating the liver, pancreas, skeletal muscle, and AT can also elicit 
acute catabolic responses (i.e., glycogenolysis and lipolysis).  
Individuals with CO demonstrate augmented sympathetic outflow when compared to non-
central adiposity phenotype (76). Compared to healthy lean individuals, obese adults have 
elevated rates of whole-body NA spillover in plasma (77). Interestingly, the degree of 
sympathetic overactivity in obese individuals appears to be dependent on body fat 
distribution with CO shown to be associated with greater sympathetic nerve activation than 
subcutaneous obesity (77, 78). The underlying cause of the observed SNS overdrive in 
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obesity is not fully understood, but is likely multifactorial and starts as part of a homeostatic 
mechanism aimed at expending the excess energy as heat rather than additional storage of 
fat. SNS activation is seen in humans following overfeeding and is decreased with fasting 
(79). The chronic increase in basal sympathetic activity is presumably an adaptive 
physiological response aimed to stimulate β–adrenergic thermogenesis in order to prevent 
further fat storage (77), but can also stimulate lipolysis to increase NEFAs, contributing to 
insulin resistance. The catecholamine-producing monocytes/macrophages that infiltrate 
white AT induce the development of thermogenic beige AT (40, 80). This previously 
unrecognized function of macrophages in instructing beige AT development and subsequent 
energy expenditure has significant implications for the role of these cells in metabolic 
disorders. 
The AT through the release of various adipokines may directly or indirectly increase 
sympathetic activity. A chronically elevated SNS outflow could in turn impair β–adrenergic 
signaling, reduce stimulation of metabolism, and evolve into a cycle that contributes to 
obesity, insulin resistance and morphologic changes in target tissues. 
Compared to the liver, pancreas, and skeletal muscle, which are also under parasympathetic 
control, AT, as stated before, is mostly innervated by sympathetic nerves (81) making it an 
important regulator of lipid mobilization. Central sympathetic outflow directly stimulates 
adipocyte lipolysis by binding to β-adrenergic receptors in white AT to activate cAMP-
dependent pathways to translocate inactive lipase. Equally, when α-AR are activated, 
lipolysis is inhibited.  
Central obesity is characterized by hyperinsulinemia, increased leptin and NEFAs release 
from excess visceral fat and reduced baroreceptor sensitivity and activation of the 
hypothalamic-pituitary-adrenal axis.  
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Downregulation of β-adrenoceptors leading to a blunted thermogenic response to food can 
potentiate insulin resistance and perpetuate the negative feedback cycle between insulin 
governing sympathetic outflows. Evidence in support of weight gain being directly related to 
decreased β-adrenergic responsiveness comes from studies that show that both short-term 
(82) and chronic (83, 84) pharmacological blockade of beta-receptors leads to an increase in 
body weight. 
Besides the central action of DA on the nervous system as a canonical neurotransmitter 
regulating cognition, motor control, mood, and reward systems, peripheral DA originated 
from other sources namely and importantly from the immune system, suggests a key role on 
neural-immune interactions (see item 1.6). Because DA does not cross the blood-brain 
barrier dopaminergic signaling in brain is functionally distinct from peripheral pathways. In 
the basal ganglia, DA is involved in the signaling of the rewarding effects secondary to food 
intake. In peripheral tissues, DA regulates pancreatic endocrine function including insulin 
release and also modulates the effects of insulin action on adipocytes. Indeed, peripheral DA 
can originate from at least three sources, i.e. neuronal fibers, adrenal medulla, and 
neuroendocrine cells found in kidney, pancreas and leukocytes with a role in regulation of 
blood pressure, sodium balance, adrenal and renal functions, as well as glucose homeostasis 
and body weight (85).  
Changes in plasma DA levels are predominantly determined by the activity of sympathetic 
nerves, which may release the precursor DA along with NA into the parenchyma of target 
organs. Some DA may be released directly into the circulation from catecholamine 
synthesizing cells of the adrenal medulla, chromaffin cells, similarly to NA and AD.  
Based on the distribution of TH immunoreactivity in gastric mucosa, many epithelial cells in 
the human stomach (including parietal cells), are capable of producing DA. Lower down in 
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the digestive tract, TH-positive epithelial cells were not detected; however, numerous lamina 
propria cells were positive for TH. This suggests that immune cells throughout the human 
gastrointestinal tract might also be capable of producing DA (86). 
 
1.6 Immune cells-a catecholaminergic organ–Opening the Pandora Box of 
Inflammatory Obesity? 
1.6.1 Pharmacology of adrenergic and dopaminergic pathways  
Dopamine, NA and AD are CA, i.e. chemical compounds with a 3,4-dihydroxyphenyl group 
(catechol) and an amine function. They represent the main CA in humans and are all 
produced from the non-essential amino acid tyrosine which is both obtained from dietary 
proteins or in turn synthesized from the essential amino acid phenylalanine by the enzyme 
phenylalanine hydroxylase. The enzyme dopamine β- hydroxylase synthesizes NA from DA, 
and phenylethanolamine N-methyltransferase converts NA to AD (87) (Figure 3). 
Dopamine, NA and, to a lesser extent, AD act as neurotransmitters in the CNS. 
Noradrenaline is also the main neurotransmitter in postganglionic neurons on the 
sympathetic nervous systems, while AD (and, to a lesser extent, NA) is the neurohormone 
secreted by chromaffin cells in medulla of adrenal glands (87). 
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Figure 3 Pathways for biosynthesis and degradation of dopamine, noradrenaline and adrenaline. 
Synthesizing enzymes and enzyme cofactors are shown close to each arrow. Tyrosine hydroxylase (TH) is the 
rate-limiting step for catecholamines synthesis and dopamine-β-hydroxylase (DBH) which converts dopamine 
to noradrenaline is, also, a key enzyme for the synthesis of catecholamines. Copyright with License Number 
3970830471544 from Springer of the manuscript Cosentino M, Marino F. J Neuroimmune Pharmacol (2013) 
8:163–179) (ref. 87). 
 
The immunological-metabolic crosstalk regulates metabolism and immune responses (88). 
Indeed, immune cells are considered biosensors for metabolic/endocrine factors (89) and 
adipocytes exhibit immune functions (90). It is not clear at present which neuroendocrine 
regulators or metabolic factors affect the immune system in obesity. 
Scientific evidence has accumulated regarding the ability of immune cells themselves to 
produce and utilize DA, NA and AD (91). 
58 
 
Coexisting in the nervous as well as in the immune system, CA become a universal language 
of a neuro-endocrine-immune modulating network which enables the nervous, endocrine, 
and immune system to regulate and fine-tune their functional responses. Through direct 
communication via sympathetic nerve fibers that innervate lymphoid organs (92), CA can 
modulate lymphocyte proliferation, differentiation, and cytokine production of human 
PBMC expressing AR (93). Human lymphocytes and PBMC were described to contain 
intracellular levels of CA (94- 97). Endogenous CA regulate, through autocrine/paracrine 
mechanisms, several immune cell functions namely, proliferation, differentiation and 
apoptosis via an autocrine loop (94, 98). 
Remarkably, immune cells, neurons and adipocytes share common signaling pathways 
mediated by CA, namely AD, NA and DA through activation of AR and dopaminergic 
receptors (DR) (93-101). Like neurons and endocrine cells, lymphocytes and phagocytes can 
produce, store, release and reuptake CA de novo (101). These cells regulate their CA-
synthesis in response to various extracellular stimuli (93). Thus, immune cells seem to 
possess not only the full cellular machinery for de novo synthesis, but also are capable of 
intracellular CA-inactivation utilizing the same classical metabolic pathway described in 
nervous and endocrine systems. 
 
1.6.2 The Adrenergic and Dopaminergic Receptors- Adrenergic and Dopaminergic 
modulation of immunity  
The effects of DA, NA and AD are mediated by receptors belonging to the 7-
transmembrane, G protein coupled receptors family. DA acts on 5 different DR grouped into 
two families according to their pharmacological profile and main second messenger 
coupling: the D1-like (D1 and D5) which activate adenylate cyclase and the D2-like (D2, D3 
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and D4) which inhibit adenylate cyclase (see Table 1) (97, 100). NA and AD act on 9 
different AR, which include three major types - α1, α2 and β - each further divided into three 
subtypes (see Table 2) (100). DR and AR ligands are currently used in the treatment of 
several non-immune conditions. DR agonists are currently used in the treatment of 
Parkinson’s disease, restless leg syndrome, and hyperprolactinemia, while antagonists are 
mainly used as antipsychotics and antiemetics. AR agonists and antagonists are used to treat 
a variety of diseases, including hypertension, angina pectoris, congestive heart failure, 
asthma, depression, benign prostatic hypertrophy, and glaucoma. Additional conditions 
where AR ligands proved useful include shock, premature labour, opioid withdrawal and as 
co-medications in general anesthesia. All the steps involved in DA, NA and AD synthesis, 
storage and release, uptake and metabolism represent the target of several drugs already in 
use for non-immune indications (e.g. cardiovascular, neurologic, neuropsychiatric).  
The SNS is, together with the hypothalamic-pituitary-adrenal axis, the major pathway 
responsible for the crosstalk between the CNS and the immune system. The relevant role of 
adrenergic pathways in the modulation of the immune response has been an important target 
of extensive scientific investigation. 
 
 
 
 
 
 
 
 
60 
 
Table1 Physiopharmacology of dopaminergic receptors 
Legend: a: in periphery, all subtypes of dopamine receptors have been observed in varying proportions in the 
kidney, adrenal glands, sympathetic ganglia, gastrointestinal tract, blood vessels, and heart; b: agonist at D5 
receptors, partial agonist at D1, D2, D3 and D4 receptors, also α2-AR antagonist; c: agonist at D1 and D5 
receptors, partial agonist at D2, D3 and D4 receptors, also α2-AR antagonist; d: partial agonist; e: full agonist 
at D2, partial agonist at D3, antagonist at D4, also full/partial agonist at D1 and D5 and α2-AR antagonist; f: 
full agonist at D2, partial agonist at D3 and D4. Copyright with License Number 3970830471544 from 
Springer of the manuscript Cosentino M, Marino F. J Neuroimmune Pharmacol (2013) 8:163–179) (ref. 87). 
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Table 2 Physiopharmacology of adrenoceptors 
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Table 2 Physiopharmacology of adrenoceptors (continued) 
Legend: a: also an α2-AR partial agonist; b: inverse agonist at α1D-AR, also an α2-AR antagonist; c: also a 
DRD3 antagonist; d: also a 5-HT2 antagonist; e: also DRD2-3 partial agonist; also dopamine receptor 
agonist/partial agonist; f: partial agonist; g: non-selective β-AR agonist; h: β1- and β2-AR partial agonist; i: 
non-selective β-AR antagonist. Copyright with License Number 3970830471544 from Springer of the 
manuscript Cosentino M, Marino F. J Neuroimmune Pharmacol (2013) 8:163–179) (ref. 87) 
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Figure 4 Schematic overview of β-AR and dopaminergic receptor pathways and of endogenous 
catecholamines in human lymphocytes in healthy subjects. Lymphocytes express both β-ARs (mainly of the 
β2 subtype) and D1-like and D2-like dopaminergic receptors, and can produce and store dopamine, 
noradrenaline and adrenaline. Cell stimulation results in β-AR (and, probably, also dopaminergic receptor) 
upregulation, as well as in increased intracellular storage of catecholamines which, upon release induced by 
appropriate stimuli, can act as autocrine/paracrine transmitters in the immune system in the nervous system as 
well as in different tissues. The process of cell activation is an integrated balance of – on one side – β-ARs and 
D1-like dopaminergic receptors, which exert an inhibitory influence, and – on the other side – by D2-like 
dopaminergic receptors, which exert a stimulatory influence. Intracellular catecholamines may also play a role 
in the regulation of activation-induced apoptosis. The scheme does not include information about α-ARs, as 
their role in the immunomodulation has received so far, few attention, and depicts the arrangement of pathways 
as it occurs in T effector lymphocytes. Different lymphocyte subsets may however exhibit distinct 
arrangements, such as in the case of CD4+CD25high T cells. Copyright with License Number 
3970830471544 from Springer of the manuscript Cosentino M, Marino F. J Neuroimmune Pharmacol (2013) 
8:163–179) (ref. 87). 
 
Released by sympathoadrenergic terminals, NA acts on β2-ARs expressed on immune cells 
inducing anti-inflammatory effects which result from both inhibition of Thelper (Th) 1 
proinflammatory cytokines (e.g. IFN-γ, IL-12, TNF-α) and enhancement of Th2 cytokines 
(e.g. IL-10 and TGF-β) (102) (Figure 4). Activation of β-ARs on human lymphocytes may, 
however, result also in immune stimulatory effects, depending on the time of exposure and 
the degree of cell differentiation and activation. It has been shown that NA may promote IL-
12-mediated differentiation of naïve CD4+ T cells into Th1 effector cells, and increase the 
amount of IFN-γ produced by Th1 cells (102). The occurrence of β2-ARs, usually with 
inhibitory functions, has been reported also on monocytes/macrophages and neutrophils, as 
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well as in CNS resident immune cells. In contrast to the anti-inflammatory effect of β-AR 
signaling, treatment of human monocytes with the α1-adrenergic receptor agonist 
phenylephrine hydrochloride promoted LPS-induced IL-1β (103) (Figure 4).  
In comparison to adrenergic pathways, dopaminergic pathways modulating immune 
responses (Figure 4) have been investigated only recently. It is now clear that DR are 
expressed in most if not all human immune cells, including T and B cells, dendritic cells, 
macrophages, microglia, neutrophils and NK cells, and that immune cells contact DA not 
only in brain but also in blood, lymphoid organs and in other peripheral tissues, such as the 
kidney and the hepatic vasculature (104). Dopamine induces activation of resting T cells in 
the absence of any other stimulating factor, however it inhibits stimulated T cells. In naïve 
human T cells, DA acts on DR expressed on these cells inducing β1 integrin-dependent 
adhesion to fibronectin (through DR D2/D3 receptors) (105), as well as increased production 
of TNF-α (through DR D3 and D1/D5 receptors) and IL-10 (through DR D2 and D1/D5 
receptors) (106). The effect also depends on dopamine concentration as well as on DR 
subtype(s) and of the specific subpopulations of immune cells (107). For instance, activation 
of D1-like receptors expressed in CD4+CD25high T lymphocytes results in inhibition of the 
regulatory functions of this cell subset, which usually suppresses the activity of effector T 
cells (98). Evidence exists for an immunomodulatory role of DA regarding the functional 
responses of NK cells, splenic cells, macrophages, B cells and microglial cells (Figure 5) 
(104, 107, 108).  
The existence of a classical pathway for the synthesis of DA, NA and AD in immune cells is 
suggested by the expression of the enzyme tyrosine hydroxylase (TH), the first and rate-
limiting enzyme in the synthesis of CA which undergoes upregulation following cell 
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stimulation, as well as by the ability of the TH inhibitor α-methyl-p-tyrosine to prevent 
intracellular enhancement of CA levels (93, 95-114) (Figure 3). 
In human lymphocytes CA are stored in reserpine-sensitive compartments, possibly through 
vesicular monoamine transporters (VMAT) similar to those expressed in neural and 
neuroendocrine cells (93, 108, 115), and CA release can be effectively induced by biological 
agents such as IFN-β (116) or by physiological stimuli such as elevation of extracellular K+ 
concentrations (117). Human lymphocytes may also express the DA transporter (DAT) (93, 
118) and possibly the NA transporter (NET) (112). Several lines of evidence support the 
functional relevance of endogenous CA in rodent and human immune cells (101, 119). In 
human immune cells, intracellular levels of CA in circulating lymphocytes from healthy 
subjects correlated with both basal and isoprenaline-stimulated cAMP production. Studies in 
human PBMC showed that stimulation with PHA induces the synthesis of CA through 
induction of TH and its pharmacological inhibition with α-methyl-p-tyrosine results in 
decreased activation-induced apoptosis (114).  
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Figure 5 Catecholamine signaling in monocyte/macrophage function. Catecholamines are recognized by α 
and β-adrenergic receptors (1). Signaling through α-adrenergic receptors is pro-inflammatory and promotes 
LPS-induced gene expression whereas β-adrenergic receptor signaling inhibits this and induces expression of 
anti-inflammatory cytokines (2). Cold temperature induces macrophage synthesis of catecholamines which act 
to increase white to beige adipose tissue conversion and energy expenditure (3). B. Sciatic and vagus nerve 
stimulation promotes dopamine synthesis (1). Dopamine receptor signaling enhances GPCR activity leading to 
increased viral entry and replication (2). Dopamine signaling also inhibits pro-inflammatory cytokine 
production (3). Abbreviations: LPS, lipopolysaccharide; GPCR, G-protein-coupled receptors. Source of figure: 
Barnes et al. Non-traditional cytokines: How catecholamines and adipokines influence macrophages in 
immunity, metabolism and the central nervous system Cytokine 2015; 72:210–219 (ref.64). Acknowledgments 
to Cytokine Editor-in-Chief, Dhan V. Kalvakolanu, M.S., PhD, for kindly allow copyright.  
 
1.7 Rationale for Peripheral Blood Mononuclear Cells as model of obesity 
study 
Circulating leucocytes, being an integral part of the immune system and the main source of 
immune cells infiltrating AT in response to obesity, are biomarker candidates for identifying 
forms of obesity (120). 
Peripheral blood mononuclear cells (PBMC) have been proposed as representative of the 
inflammatory status in obesity (121), potential biomarkers of weight-loss strategies (122) 
and, as well, model to study the response of energy homeostasis-related genes to acute 
changes in feeding conditions (123). Leptin expression in human PBMC was suggested to 
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have a role in blood pressure regulation (124). However, using either total leucocyte counts 
or the main leucocyte classes has so far fallen short from being clinically useful in risk-
stratification of the individual obese patient. The full repertoire of leucocyte subclasses has 
yet to be identified. Specific molecular markers are continuously being discovered and 
proposed to signify unique subclasses, which may prove to be more tightly associated with 
better defined obesity subphenotypes. 
Studies attempting to link a specific circulating leucocyte population to AT inflammation are 
scarce. Since AT, particularly visceral fat, is usually not available for examination, 
identifying circulating blood cells that will signify the state of intra-abdominal fat 
inflammation would be very useful clinically. 
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1.8 Aims 
Assessment of health risk associated with excess adiposity requires, for one hand, an 
accurate measurement of obesity and for another hand identification of predictors of 
subclinical inflammatory obesity that can be important tools for early therapeutic 
interventions in obesity-related co-morbidities. 
It is not clear at present which neuroendocrine regulators or metabolic factors affect 
specifically the immune system in a complex multisystem disorder such as obesity. Whether 
peripheral catecholaminergic system is involved in the low-grade inflammation linked to 
obesity is unknown. The migration of PBMC towards sites of inflammation such as the AT 
is crucial to the development of sustained tissue inflammation. Circulating PBMC are 
exposed to systemic factors, such as dyslipidemia and inflammatory molecules and are 
directly involved in the low-grade chronic inflammation related to obesity. The expression 
of both AR and DR in immune cells under an obesogenic state is unknown. The major aims 
of this thesis are the following: 
i. To identify subclinical inflammatory obesity predictors; 
ii. To investigate whether WC defining obesity is more sensitive for early 
metabolic markers and inflammatory changes in monocytes subsets than BMI 
obesity defined; 
iii. To investigate whether the expression of catecholaminergic receptors in 
PBMC has a different pattern in central obesity;  
iv. To investigate whether the expression of catecholaminergic receptors in 
PBMC is associated with metabolic/inflammatory markers; 
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Chapter 2: Paper 1- Predictors of subclinical inflammatory 
obesity: plasma levels of leptin, very low-density lipoprotein-
cholesterol and CD14 expression of CD16 positive 
monocytes.  
 
2.1 Preface to Paper 1 
Our drive in this work was, in first place, to find early markers for inflammatory obesity in 
order to precociously intervene therapeutically and contribute for prevention of 
comorbidities obesity-associated that threaten human life span. The first manuscript 
identifies a prediction model of subclinical inflammatory obesity that is discussed. 
 
2.2 Paper 1 
Leite F, Leite A, Santos A, Lima M, Barbosa J, Cosentino M, Ribeiro L. Predictors of 
subclinical inflammatory obesity: plasma levels of leptin, very low-density lipoprotein-
cholesterol and CD14 expression of CD16 positive monocytes. Accepted for publication in 
Obesity Facts (manuscript nº 201608007). 
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Abstract 
 
Background: Predictors of subclinical inflammatory obesity (SIO) can be important tools 
for early therapeutic interventions in obesity-related co-morbidities. Waist circumference 
(WC) and body mass index (BMI) have different SIO sensitivity. We aimed to (1) identify 
SIO predictors and (2) investigate whether CD16+ monocytes are associated with BMI-
(general) or WC-(central) defined obesity. Methods: Anthropometric and 
metabolic/endocrine (namely catecholamines, adrenaline and noradrenaline) parameters 
were evaluated, and CD16+ monocytes were studied by flow cytometry in the peripheral 
blood from 63 blood donors, and compared and correlated to each other. Multiple linear 
regression analysis was performed to identify variables that best predict SIO. Results: 
CD16+ monocyte counts were similar in BMI and WC groups. CD16+ monocytes from 
centrally obese (CO) showed a more inflammatory pattern, as compared to non-CO subjects. 
WC was sensitive to lipidemia and, in CO subjects, lipidemia was associated with a more 
inflammatory phenotype of CD16+ monocytes. These differences were not noticed between 
BMI groups. Adrenaline was correlated with CD16+ monocyte expansion with a lower 
inflammatory pattern. Leptin, very low-density lipoprotein–cholesterol (VLDL-C), CD14 
expression of CD16+ monocytes were found to be central obesity predictors. Conclusions: 
WC, but not BMI-defined obesity, was associated with a more inflammatory pattern of 
CD16+ monocytes, without monocyte expansion, suggesting that a monocyte maturation 
process rather than an independent arise of CD16+ monocytes occurs in CO. Thus, in a 
population with low cardiovascular low-risk, leptin, VLDL-C and CD14 expression of 
CD16+ monocytes predict CO, constituting a putative tool for screening of SIO.  
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Introduction 
 
Obesity is a major threat to human health and lifespan. In the pathogenesis of obesity and its 
comorbidities, increasing evidence points to a pivotal role of the crosstalk between 
metabolic and immune systems, with adipocytes exhibiting immune functions and immune 
cells being influenced by endogenous metabolites, namely lipids [1, 2]. Obesity induces 
macrophage infiltration into white adipose tissue (AT) in both humans [3] and mice [4], 
orchestrating local and systemic inflammation, and consequently leading to insulin 
resistance, T2D and cardiovascular disease (CVD). The recruitment of circulating 
monocytes into the AT is an early event in obesity-induced AT inflammation [1]. Although 
monocyte counts have a strong and independent relationship with the overall cardiovascular 
(CV) risk [5], the role of the distinct circulating monocyte subsets in obesity is still 
undetermined.  
Even though inflammation remains a key mechanism underlying this pathophysiology, 
finding sensitive tools towards the identification of subclinical inflammatory obesity (SIO) 
is challenging. In the context of our study, SIO is defined as the presence of inflammatory 
markers in a healthy population without obesity-associated metabolic or cardiovascular 
diseases [6]. Discovery of biomarkers to allow earlier detection of inflammatory obesity will 
help to assess therapeutic effectiveness for obesity-related comorbidities such as CVD and 
cancer, which are increasing in incidence worldwide [7].  
Body mass index (BMI) is the most used and widely accepted method in epidemiological 
studies to measure obesity [8]. However, BMI neither indicates fat distribution nor does 
distinguish fat mass from fat-free mass, which have opposite associations with health risk 
[8]. In contrast, waist circumference (WC), a measure of central adiposity, has been found to 
be highly correlated with visceral fat measured by computed tomography [9], and better 
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estimates obesity-associated CV risk in comparison to BMI [9]. Obesity, mainly the central 
type, is associated with both a chronic inflammatory state and sympathetic nervous system 
overactivity [1, 10]. The catecholamines (CA), adrenaline (AD) and noradrenaline (NA), 
potent modulators of neuroendocrine/immune/inflammatory networks, regulate monocyte 
inflammatory response during health and disease [11]. The crosstalk between adipokines and 
CA suggests a role for these molecules linking obesity to inflammation [12]. Among 
immune cells, monocytes are key players in obesity-associated systemic inflammatory 
processes and in the development of CVD [1]. In obesity, visceral adipose tissue becomes 
infiltrated by a large number of monocytes mainly originated from the peripheral blood [4]. 
Two major peripheral blood (PB) monocyte subsets have been described, according to their 
immunophenotype: classical CD14+CD16- (CD16-) and non-classical CD14+CD16+ 
(CD16+) subsets [13]. CD16+ monocytes have also been shown to have lower expression of 
both CD11b (integrin alpha M, ITGAM, or, complement receptor type 3, CR3), and CD36 
(fatty acid translocase, FAT, a scavenger receptor), as compared to CD16-monocytes, and 
they are considered “proinflammatory” cells since they exhibit a macrophage-like phenotype 
with enhanced antigen-presenting capacities, higher endothelial affinity and production of 
proinflammatory cytokines [13] [14]. Accordingly, increased percentages and/or absolute 
numbers of CD16+ monocytes have been described in the PB from patients with 
inflammatory pathologies, such as sepsis, rheumatoid arthritis, and infections [13], and in 
patients with a high cardiovascular mortality risk [15]. Rogacev et al. described a weak 
association between CD16+ monocyte counts and BMI in a healthy population [16]. 
However, the pathophysiological significance of these findings is still controversial. 
Moreover, in inflammatory obesity, it is uncertain whether there is an expansion of CD16+ 
cells or a maturation process from classical to non-classical monocytes and if CA (AD and 
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NA) are associated with monocytes characteristics observed in that condition. Previously, 
we have demonstrated that central obesity (CO) is associated with a higher immune 
inflammatory pattern and a downregulation of dopaminergic pathways in peripheral blood 
mononuclear cells [17].  
The main aims of our study were (1) to identify predictors of SIO, (2) to investigate whether 
proinflammatory CD16+ monocytes are preferentially associated with BMI-defined or WC-
defined obesity and (3) to evaluate which anthropometric, metabolic or endocrine 
parameters are associated with CD16+ monocyte characteristics.  
Our work, for the first time, addresses the prediction of SIO, a major issue in public health 
given its comorbidities associated with a decrease in human life span.    
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Methods 
 
Methods 
 
Study population 
This study was conducted in 65 blood donors from the Blood Bank of Clinical Hematology 
Department of Centro Hospitalar of Porto (CHP), Portugal; it meets the standards of the 
Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, 
and 1996 [JAMA 1997;277:925-926], and was approved by the Ethical Committee and 
Research Office, and authorized by the administration board of CHP, being registered with 
the identifier 072/09 (047-DEFI/065-CES). All participants signed a written informed 
consent, after being ware about the objectives of the study and the confidentiality of the 
data. The individuals met the selection criteria for blood donation and were not under any 
medicines during the previous month. Two blood donors that were not fasting for, at least, 
12 hours at the time of blood withdrawal were finally excluded. After 5 minutes of rest, 
blood pressure (BP) systolic blood pressure (SBP) and diastolic blood pressure (DBP) was 
measured twice and the mean values were used in the analysis.  
 
Anthropometrics 
Height (in meters) was based on an identification document and confirmed by medical 
record. Body weight was measured to the nearest 100 g on electronic weight scales. Body 
mass index was calculated by dividing weight by squared height and expressed in kg.m-2. 
Participants, all Caucasian, were divided into three BMI categories that correspond to the 
definitions of normal weight (NW, BMI from 18.5 to 24.9 kg.m-2), overweight (OW, BMI 
from 25.0 to 29.9 kg.m-2), and obesity (OB, BMI30.0 kg.m-2), according to the World 
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Health Organization guidelines (WHO) [8]. Waist circumference was measured with a 
flexible tape at the level midway between the lowest rib margin and the iliac crest. As stated 
by the International Diabetes Federation, CO was defined as WC ≥0.80 m in women and 
≥0.94 m in men [18]. 
 
Biochemical analysis 
Blood samples were taken from all subjects under standardized conditions. Fasting plasma 
glucose, triacylglycerol (TAG), total cholesterol (TC), high-density lipoprotein-cholesterol 
(HDL-C), low-density lipoprotein-cholesterol (LDL-C), and very low-density lipoprotein-
cholesterol (VLDL-C), were measured with turbidometry and spectrophotometry 
methodology using the Cobas® 8000 autoanalyzer (Roche, Rotkreuz, Switzerland). 
Glycosylated hemoglobin (HbA1c) measurements were done by High Performance Liquid 
Chromatography (HPLC), using the Hi-Auto A1c HA-8140 HPLC (Menarini Diagnostics, 
Florence, Italy). Plasma CA (NA and AD) were determined by HPLC with electrochemical 
detection (HPLC-ED) (Chromosystems Instruments & Chemicals GmbH, Munich, 
Germany). Determination of cortisol in plasma was performed with an 
electrochemiluminescence immunoassay (Elecsys Systems analyzer Roche, Roche 
Diagnostics International Ltd Rotkreuz, Switzerland). Leptin levels were measured in serum 
by solid phase two-site enzyme immunoassay (Mercodia Leptin ELISA, Mercodia AB, 
Sylveniusgatan 8A, Uppsala, Sweden). High-sensitivity C-reactive protein (hsCRP) (mg/L) 
was determined by nephelometry (CardioPhase™ hsCRP – BnProSpec Siemens Healthcare 
Diagnostics Inc. New York, United States), and was categorized by cardiovascular event 
risk groups: <1- low, ≥1 to <3 –intermediate and above 3 - high risk, as described before 
[19].  
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Flow cytometry assay of monocytes 
Monocytes were analyzed in fresh ethylenediaminetetraacetic acid tripotassium (EDTA-K3) 
anti-coagulated blood samples by means of flow cytometry, using a previously described 
technique [20]. The enumeration and the immunophenotypic analysis of monocytes were 
performed. Immunophenotypic studies were done through a whole blood stain-lyse-and-
then-wash method, a direct immunofluorescence technique using the following a four-color 
panel of monoclonal antibodies (mAbs): mouse anti-human CD36 conjugated with 
fluorescein isothiocyanate (FITC) (clone FA6.152, IgG1), mouse anti-human CD16 
conjugated with phycoerythrin (PE) (clone 3G8, IgG1), mouse anti-human CD14 conjugated 
with PE-Cy5 (IgG2a, clone RMO52) all obtained from Beckman Coulter (catalogue 
numbers IM0766U, IM1238U and IM2640U, respectively), and mouse anti-human CD11b 
conjugated with allophycocyanin (APC) (IgG2a, clone D12) obtained from Becton 
Dickinson (BD) (catalogue number 333143). Data acquisition was carried out on a 
FACSCalibur flow cytometer (BD), using the Cell Quest software program (BD). 
Information on a minimum of 2x105 events was acquired for each staining and stored as 
FCS data. The Paint-a-Gate Pro software program (BD) was used for data analysis. 
Monocytes were quantified based on the CD14 expression, while CD16 was used to 
differentiate classical (CD16-) and non-classical (CD16+) monocyte populations (fig. 1). 
The median fluorescence intensity (MFI) of CD14, CD36 and CD11b was assessed in each 
subset and expressed as fluorescence arbitrary units (AU). The forward light scatter (FSC), 
which is related to cell size, and sideward light scatter (SSC), which correlates with cell 
complexity/granularity, were also measured. The ratio for each parameter between 
CD14+CD16+ non-classical monocytes and CD14+CD16- classical monocytes in each 
individual was calculated, to overcome inter-individual variations. 
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Instrument setup, calibration and daily monitoring was performed with the protocols in use 
in our laboratory at the time of the study. Briefly, for instrument setup and calibration, 
unstained cells (auto-fluorescence controls) were used to adjust FSC and SSC detector 
settings so that cells of interest were displayed on scale. Next, also using unstained cells and 
gating on lymphocytes, FL1, FL2, FL3 and FL4 detector settings were adjusted so that auto-
fluorescence background was roughly within the first decade of the log scale of the 
respective fluorescence histogram. Subsequently, electronic compensation was performed by 
running cell samples stained individually with FITC-, PE-, PE-Cy5- and APC-conjugated 
anti-CD8 mAbs antibodies (single stains). Finally, compensation was checked by running 
cell samples stained simultaneously with FITC-, -PE, -PE-Cy5 and -APC conjugated mAbs 
staining mutually exclusive cell populations. Daily control was performed using Calibrite 
beads and monitored by plotting MFI values in Levy Jennings charts.  
 
Blood cell counts 
Blood cell counts were obtained using a Coulter LH750 automated hematology analyzer 
(Beckman Coulter – BC, Miami, FL). Absolute counts of total, CD16- and CD16+ 
peripheral blood monocytes, expressed as numbers of cells / l, were calculated using a dual 
platform method, in which total WBC counts derived from the hematology analyzer and the 
correspondent percentages of monocytes were obtained by flow cytometry. 
 
Statistical analysis 
The modified Kolmogorov-Smirnov test with the correction of Lilliefors was used to 
evaluate the fit of the data to a normal distribution. Variables were summarized using 
relative and absolute frequencies, mean and standard deviation, median (interquartile range 
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(25th and 75th percentiles). To compare the quantitative independent variables, we used 
bivariate statistical analysis ANOVA with Bonferroni post hoc testing (comparisons 
between more than 2 groups), or non-parametric Mann-Whitney (comparison between 2 
groups) and Kruskal-Wallis (comparison of more than 2 groups) tests for normal and non-
normal distributed data, respectively. Correlations were assessed by non-parametric 
Spearman rank analysis. The Pearson Chi-Square test was used to compare the distribution 
of qualitative independent variables. Multiple linear regression analysis was performed to 
identify the variables that best predict central obesity after controlling for potential 
confounders. Linear regression models require only two subjects per variable for adequate 
estimation of regression coefficients, standard errors, and confidence intervals [21]. 
Variables that in the univariate analysis showed statistical significance below 5% (p<0.05) 
were included in the regression. Data analysis was performed using the SPSS version 22.0 
(SPSS, Chicago, IL, USA). P-value lower than 0.05 was considered statistically significant. 
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Results 
 
Baseline characteristics and anthropometrics, metabolic/endocrine parameters and hsCRP 
in BMI and WC groups 
The baseline characteristics of the study sample are shown in table 1. The mean age (years) 
of the individuals divided either by BMI or CO groups was similar (NW=38±11 vs 
OW=40±11 vs OB=44±11); F (2, 60) =1.199; p=0.309, (with CO=42±10 vs without 
CO=36±11); F (1, 61) =3.855; p=0.054, respectively. Considering gender distribution, 
55.6% were male. The prevalence of BMI-defined OW/OB and of WC-defined CO was 
75% and 73%, respectively. Diastolic blood pressure (mm Hg) and leptin plasma levels 
(ng/mL) in OB were significantly higher than in both OW and NW (89±9) vs (80±9) vs 
(73±8); F (2, 60) =12.748; p<0.001, 1.17 (0.85-3.47) vs 0.50 (0.30-1.05) vs 0.20 (0.04-
0.63); p=0.002, respectively. Mean DBP in OW was also higher than in NW (p=0.025). OB 
individuals also presented higher SBP than NW (144±16) vs (129±16); F (2, 60) =4.413; 
p=0.016. Subjects with CO in comparison with those without CO had not only higher DBP 
(82±11 vs 76±7; F (1, 61) =4.244; p=0.044) and leptin levels 0.870 (0.510-1.300) vs 0.100 
(0.040-0.210); p=0.006 but also showed differences in lipid profile. These include higher 
levels of TC (200±35 vs 178±35; F (1, 59) =4.978; p=0.029), TAG 100 (68-135) vs 78 (50-
99); p=0.034 and VLDL-C 20 (14-27) vs 16 (10-20); p=0.033 (mg/dL). None of the other 
metabolic/endocrine parameters were significantly different between BMI and WC-groups. 
The plasma levels of hsCRP (mg/L) [data as median and interquartile range (25th and 75th 
percentiles)] were neither different between BMI-defined [1.410 (0.352-1.920) vs 1.190 
(0.571-2.250) vs 3.020 (1.090-3.860); p=0.171, respectively for NW, OW and OB] nor 
between WC-defined groups [1.530 (0.764-3.560) vs 0.757 (0.469- 1.750); p=0.099, 
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respectively for groups with and without CO]. Plasma leptin values (ng/mL) were different 
between hsCRP-defined cardiovascular risk groups [0.320 (0.100-0.850) vs 0.615 (0.480-
1.140) vs 3.100 (0.800-5.170); p=0.011, respectively for low, intermediate and high risk 
groups]. hsCRP-defined groups did not show sensitivity for other studied parameters. 
However, hsCRP plasma levels correlated with DBP, VLDL-C, TAG and leptin [(ρ=0.286; 
p=0.027); (ρ=0.276; p=0.033); (ρ=0.284; p=0.028); and (ρ=0.397; p=0.011), respectively]. 
 
Frequency and immunophenotype of monocyte subpopulations in BMI- and WC-defined 
groups 
In the whole population, total monocytes were on average 439 cells/μL (table 1), and were 
not different in both BMI- (446±141 vs 445±151 vs 422±188; F (2, 60) =0.121; p=0.886, 
respectively for OB, OW and NW) and WC-defined groups (425±150 vs 479±174; F (1, 61) 
=1.488; p=0.227, respectively for CO and non-CO individuals). Classical CD16- monocytes 
accounted for 89% and inflammatory CD16+ monocytes 11% of total monocytes (table 2). 
As previously described [14], CD16+ monocytes showed lower cellular 
complexity/granularity (SSC) and lower expression of CD14, CD36 and CD11b, as 
compared to CD16- monocytes (table 2). The frequency and the immunophenotype of either 
CD16+ or CD16- monocytes in BMI-defined groups were similar. However, CD16+ 
monocytes from CO subjects showed a more inflammatory pattern, with lower SSC and 
lower expression of CD14, as compared with subjects without CO, as evaluated by the ratio 
of SSC and CD14 expression on CD16+ and CD16- monocytes in each individual (p = 
0.003 and p=0.017, respectively) (table 3). 
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CD16+ monocytes and anthropometric and metabolic/endocrine parameters in BMI- and 
WC-defined groups 
In the whole sample, plasma levels of adrenaline correlated positively with both CD16+ 
monocyte size (FSC) and CD14 expression (fig. 2). In BMI-defined OB subjects, CD14 
expression was negatively correlated with plasma TC ( = -0.764; p = 0.006) and, similarly 
to whole population, adrenaline was correlated with the FSC of monocytes ( = 0.619; p = 
0.032).  
In CO subjects, AD correlated positively with the number and with the immunophenotype 
characteristics of CD16+ monocytes, namely, size (FSC), complexity (SSC), and CD14 and 
CD11b expression (table 4).  
No other associations between anthropometric, metabolic/endocrine parameters, namely 
leptin, and CD16+ monocytes characteristics (counting and phenotype) were verified.  
 
CD16+ monocytes and anthropometric and metabolic/endocrine parameters: impact of 
gender 
The female/male ratio was different between CO groups and not verified among BMI groups 
(table 3); thus, we analyzed the differences between genders concerning the anthropometric, 
metabolic and endocrine variables in whole population (table 1). Relatively to the monocyte 
subsets, women, comparatively to men, showed lower numbers of CD16- monocytes 
(cells/L) 343±99 vs 424±149; F (1, 60) =5.994; p=0.017] but similar numbers CD16+ 
monocytes 41±28 vs 61±63; F (1, 60) =2.529; p=0.117], respectively. The ratio of CD14 
expression on CD16+ and CD16- monocytes was lower in female in comparison to male F 
(1, 60) =4.953; p=0.030 (table 1), indicating a more inflammatory pattern of CD16+ 
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monocytes in women. No other differences were noticed between genders in relation to 
monocytes characteristics. 
The number of CD16+ monocytes did not correlate neither with the metabolic nor the 
endocrine parameters in both women and men. The plasma levels of LDL-C were found to 
correlate positively with a more inflammatory phenotype of the CD16+ monocytes in both 
female and male SSC (ρ=-0.394; p=0.042); CD14 (ρ=-0.385; p=0.033) respectively]. 
Adrenaline, as in whole sample, also correlated positively with CD16+ monocyte size (FSC) 
in both females (ρ=0.472; p=0.013) and males (ρ=0.405; p=0.020). In females, AD was 
correlated with a less inflammatory pattern of CD16+ monocytes: SSC (ρ=0.417; p=0.031); 
CD14 (ρ=0.411; p=0.041)]. On the contrary, in males, AD was inversely correlated with the 
expression of CD36 (ρ=-0.362; p=0.038). Noradrenaline was correlated with a higher 
inflammatory pattern of the CD16+ monocytes in females CD11b (ρ=-0.618; p=0.019] but 
this correlation was not verified in males. 
We performed a multiple linear regression analysis in order to find a predictive model for 
CO, controlling for gender. The independent variables weight, height, SBP, HDL-C, VLDL-
C, TAG, adrenaline, leptin, total number of monocytes, classical monocytes (CD16-) 
counting and CD14 ratio were included in the analysis, as they were significantly different 
between genders. We found that 33.7% of the CO is explained by a model that includes 
leptin, CD14 ratio, VLDL-C (R2 =0.337; Z=6.258; df 3; p=0.002). 
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Discussion 
 
The main findings of the present study are threefold. First, we identified a prediction model 
of SIO identified by CO, but not by BMI; CO is predicted in more than one third with a 
model that includes the determination of plasma levels of leptin and VLDL-C, and CD14 
expression in monocytes subsets. Second, in SIO, CD16+ monocytes showed a “more 
inflammatory” phenotype signature, although no increase in the frequency or absolute 
number of proinflammatory monocytes has been observed, suggesting that the maturation 
process from classical to proinflammatory monocytes already occurs in early stages of 
inflammatory obesity. Third, catecholamines (AD and NA) were associated with the 
characteristics of CD16+ monocytes with a putative immunomodulatory role in obesity.  
A review of determinants for subclinical inflammation in obesity, namely in children, 
described a significant increase in C reactive protein (CRP), interleukin (IL)-6 and leptin 
with increasing adiposity, independent of age [22]. Total dietary fat and percentage of 
energy from fat were significant predictors of CRP concentration, independently of BMI [6]. 
Our work found that leptin and VLDL-C plasma levels, and CD14 expression on CD16+ 
monocytes are predictors of inflammatory obesity in a low cardiovascular risk population. 
For one hand, understanding that more than one third of inflammatory obesity is explained 
by these parameters, this data may contribute to clarify why the adiposity measurements 
(general and/or central) per se fail in prediction of CVD [22]. The interpretation of the 
results from a collaborative analysis of 58 prospective studies was that measures of general 
and central obesity did not improve CVD risk assessment when information is available on 
SBP, diabetes and lipids [23]. Moreover, it is widely accepted that the cluster metabolic 
syndrome is explained by underlying inflammation which trigger is not completely 
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understood. Our model predicts obesity-associated inflammation. Leptin has a main 
inflammatory / immunomodulatory role [24] and increased levels of VLDL-C is one of the 
first events of dyslipidemia associated to obesity [25]. In addition, the more inflammatory 
pattern observed on CD16+ monocytes from CO subjects may facilitate their transmigration 
to AT and subsequent local inflammation. Prospective studies would be necessary to 
evaluate our predictive model of inflammatory obesity in CVD risk assessment. 
In the present work, a CV low-risk population was recruited to study SIO. Central obesity 
was associated with dyslipidemia and a distinct phenotypic more inflammatory pattern of 
CD16+ monocytes (with no expansion), while no significant differences were noticed 
between BMI groups. Using a flow-cytometric approach, we differentiated two monocyte 
subsets as described before [13]: classical CD16- monocytes and non-classical CD16+ 
monocytes (with lower SSC and lower expression of CD14, CD36 and CD11b 
comparatively to classical monocytes). Although an intermediate subset of CD16+ 
monocytes has been reported [26], sharing with the classical subset the gene expression 
profile [27] and a higher expression of CD14 [26], its biological role remains unclear. This 
intermediate subset, that in physiological states constitutes a very small percentage in 
circulation, seems to represent a transitional maturation stage from CD16- to CD16+ 
monocytes [26]. Moreover, it has been demonstrated that non-classical monocytes (and not 
the intermediate monocytes) are the primary inflammatory monocytes in acute and chronic 
inflammatory conditions [28]. Our findings, showing an association between CO and a 
subset of CD16+ cells with lower expression of CD14, would suggest that CD16+ 
monocytes more likely belong to the non-classical subset.  
According to our results, several studies in human chronic pathologies associated with low 
grade inflammation did not find changes in CD16+ monocyte counts [29-31]. On contrary, 
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Rogacev et al. [16] have shown a weak correlation between BMI and CD16+ monocyte 
counts (total CD16+ and intermediate but not non-classical monocyte subsets). Curiously 
enough, Berg et al. [32] showed that elevated numbers of CD16- monocytes predicted 
cardiovascular events, independently of gender, age, current smoking, HDL-C and the 
presence of diabetes and hypertension.  
The expression of adhesion molecules (CD11b) [33] and scavenger receptors (CD36) [34], 
in peripheral blood monocytes have been used to characterize the inflammatory response in 
metabolic disorders because of their involvement in the pathogenesis of diabetes and obesity 
[35, 36]. CD11b has been associated with high fat diet induced obesity [37] and carotid 
intima-media thickness [38], and CD11b expression was described as lowest for non-
classical monocytes after LPS stimulation [39] and in a rodent model of T2D [40]. Results 
concerning CD36 atherogenicity are, also, contradictory, since an increase [35] or deficiency 
[41] of its expression have been associated with the pathogenesis of atherosclerosis and 
CVD.  
These contradictory results relatively to monocytes subsets characteristics (counting and 
phenotype) may be explained by discrepancies in gating strategies for flow cytometric 
characterization and purification protocols contributing to significant changes in receptor 
expression. We have adopted whole blood and staining protocol to perform the flow 
cytometric study in a robust gating strategy.  
Circulating monocytes undergo phenotypic modifications due to exposure to systemic 
environmental factors [2]. Plasma lipids and leptin are immune modulators [2, 24], and they  
could have affected the phenotype of CD16+ monocytes. Circulating lipids may also 
influence the function of the immune cells [2]. Despite the regulatory role of leptin on 
human monocytes [42], it seems unlikely that this adipokine could be the only factor 
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explaining the more inflammatory pattern observed on CD16+ monocytes from CO subjects, 
as its levels were also elevated in general obese. On the other hand, individuals with CO 
showed significantly higher levels of TAG, TC and VLDL-C comparing to those without 
CO. Furthermore, BMI, frequently associated with dyslipidemia [1], was not sensitive for 
differences in lipid plasmatic profile. Apart from BMI-defined obesity has missed the 
detection of subclinical inflammation in our study, it has also been reported that visceral fat 
measurements elucidate relationships between obesity and cancer otherwise no significant 
when evaluated by BMI [43]. 
CD16+ monocytes seem to reside in a marginal pool mobilized by a catecholamine-
dependent pathway [44]. In CO, AD was correlated with the number, size and with a lower 
inflammatory pattern of CD16+ monocytes. This suggests that AD is associated with the 
expansion of this monocyte subset, as already described in stressful conditions such as 
coronary artery disease [45], but with a less inflammatory phenotype, in accordance with 
Takahashi et al. [46]. Our work also suggests that catecholamines, AD and NA, have an 
immunomodulatory role in obesity. The adrenergic regulation of human monocytes was 
recently reviewed [47]. On human monocytes, even if under certain conditions 
proinflammatory responses may arise, the predominant view is that β adrenoceptors (β-AR) 
activation is usually anti-inflammatory and immunosuppressive. In this context, the putative 
immune effects of β-AR agonists in CO requires further investigation.  
Usually correlated with adiposity [48], hsCRP was not a useful marker for SIO in our 
population with low cardiovascular risk. Others have also described a non-linear relation 
between hsCRP concentration and adiposity [49]. Although we have found association 
between hsCRP and DBP, VLDL-C, TAG and leptin, the cardiovascular risk groups defined 
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by hsCRP only differentiated plasma levels of leptin. Indeed, leptin may mediate the relation 
between hsCRP and obesity [49]. 
Our study describes a stronger association of inflammation and obesity in females, which is 
in line with the results of Thorand et al [50]. Indeed, women showed higher levels of leptin 
usually associated to inflammatory immune responses [24]. Moreover, catecholamines 
behave differently by gender [51]. Adrenaline plasma levels were associated with a less pro-
inflammatory CD16+monocyte phenotype in females and with a higher level of 
inflammation in males. In opposite, NA was associated with a higher inflammatory 
phenotype only in females. These data could be explained by higher percentage of adiposity 
in females and differences in endogenous hormones. 
Our work suggests that in SIO, dyslipidemia and leptin could induce a monocyte maturation 
process rather than an independent arise of CD16+ monocytes. Moreover, our model 
explaining a significant part of CO can be an important tool for early therapeutic 
interventions to reduce health risks associated to obesity.  
In a low CV risk population, the central, contrary to general, adiposity measure was 
sensitive to metabolic risk factors and to a more pro-inflammatory pattern of CD16+ 
monocytes (reflecting a higher activation of the innate immune system). Our findings seem 
very challenging to further investigate in an early phase of CO the phenotypic pattern of 
circulating monocytes, and its relationship with migratory and inflammatory functions.  
 
Conclusions 
Central, and not general, obesity identified subclinical inflammation. A model, that includes 
the determination of plasma leptin and VLDL-C levels and CD14 expression in monocytes 
subsets, predict and explain a significant part of CO. Our work suggests that, in SIO, 
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dyslipidemia and leptin induce a monocyte maturation process rather than an independent 
arise of CD16+ monocytes and, also suggests catecholamines (AD, NA) immunomodulation 
in obesity. The stronger association found between CO and cardiometabolic risk factors in 
comparison with general obesity assessed by BMI should consider WC a priority tool for the 
screening of inflammation in populations with low cardiovascular risk. 
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Table 1 Baseline characteristics of study participants (n=63) 
Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, 
glycated hemoglobin; TAG, triacylglycerol; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density 
Variable Data min-max Normal range F/M 
Age(years) 40±11 20-63 - ns 
Weight(kg) 77.1±13.3 51-120 - **(70±10 /83±13) 
Height (m) 1.67±0.09 1.50-1.87 - **(1.60±0.07 /1.73±0.06) 
BMI(kg.m-2) 27.6±4.2 19.6-40.1 - ns 
WC (m) 0.97±0.12 0.75-1.24 - ns 
SBP(mm Hg) 134±15 103-177 <130 **(127±13 /140±14) 
DBP(mm Hg) 80±10 61-107 <85 ns 
Glycemia(mg/dL) 86±9 67-115 70-105 ns 
HbA1c (%) 5.2±0.3 4.5-5.8 3.8-5.6 ns 
TC (mg/dL) 194±36 117-283 0-200 ns 
HDL-C (mg/dL) 50±15 25-91 35-55 *(57±15 /45±12) 
LDL-C (mg/dL) 123±33 60-209 0-130 ns 
VLDL-C (mg/dL)a 19 (13-25) 6-58 3-56 *15 (10-20) /23 (15-28) 
TAG (mg/dL)a 94 (67-124) 32-475 40-160 *75 (51-99) /116 (76-140) 
NA (pmol/L)a 690 (395-1552) 40-3760 709-4019 ns 
AD (pmol/L)a 154 (81-227) 55-965 <328 *151 (81-185) /163 (103-279)) 
Cortisol(g/dL)a 15 (13-18) 6.4-28.4 6.2-19.4 ns 
Leptin (ng/mL)a, b 0.63 (0.28-1.10) 0.003-5.3 2-5.6 **1.05 (0.70-2.09) /0.31 (0.10-0.50) 
hsCRP (mg/L)a, c 1.460 (0.617-3.015) 0.150-17.800 
< 1.0 low risk 
1.0 <3.0 
intermediate risk 
>3.0 high risk 
ns 
Leucocytes (cells/L) 6494±1585 3500-11600 4500-13000 ns 
Monocytes (cells/L) 439±157 82-964 400-500 *(384±107 /483±177) 
CD14 expression ratio 
(CD16+/CD16- 
monocytes) 
0.40±0.17 0.14-0.87 - *(0.35±0.14 /0.44±0.17) 
109 
 
lipoprotein-cholesterol; VLDL-C, very low-density lipoprotein-cholesterol; NA, noradrenaline; AD, adrenaline; hsCRP, high-sensitivity C 
reactive protein. Data are shown as: mean ±standard deviation (SD) for normally distributed; (a) non-parametric data as median 
(interquartile range); or percentage as appropriate. (b) n=41. (c) n=60. ANOVA or non-parametric Mann-Whitney test was used to 
compare quantitative independent variables by gender for normal or non-normal distributed data, respectively. F/M, female/male ratio = 
28/35; ns -nonsignificant; * p (level of significance) <0.05 and ** = p<0.001. 
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Table 2 Immunophenotypic characterization of CD16+ and CD16- monocytes in the whole 
population of study participants 
 
Abbreviations: FSC, forward light scattered; SSC, sideward light scattered; p, level of significance. The median 
fluorescence intensity of CD14, CD36 and CD11b was assessed in each subset and expressed as fluorescence arbitrary 
units. Data are presented as mean ±standard deviation (SD) or percentage, as appropriate. T test paired was used for the 
comparison of paired variables. Significant differences are in bold face.  
 
 
CD16+ CD16- 
ratio CD16+/ 
CD16- 
p 
Cells/μL 52±51 387±134 0.14±0.10 <0.001 
% of total monocytes 11.4±6.8 88.6±6.8 0.14±0.10 <0.001 
FSC 557±65 556±63 1.0±0.03 0.654 
SSC 410±53 481±45 0.85±0.06 <0.001 
CD14 892±558 2384±1522 0.40±0.17 <0.001 
CD36 317±138 740±205 0.44±0.15 <0.001 
CD11b 82±72 212±301 0.59±0.32 0.006 
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Table 3 Immunophenotypic characteristics of CD16+ and CD16- monocytes in the study participants categorized by BMI and by WC 
Abbreviations: BMI, body mass index; NW, normal weight; OW, overweight; OB, obese; WC, waist circumference; CO, central obesity; FSC, forward light scattered; SSC, 
sideward light scattered. The median fluorescence intensity of CD14, CD36 and CD11b was assessed in each subset and expressed as fluorescence arbitrary units. Data are 
presented as mean ±standard error of the mean (SEM) or percentage as appropriate. ANOVA was used for comparison between the 3 groups. (a)Pearson Chi-Square test was used 
to determine differences of F/M (female/male) n (number of individuals) between groups; F, Snedcor’s distribution; df, degree of freedom; p level of significance. 
 BMI Waist Circumference 
NW OW OB p   Without CO With CO p 
F/M (n)   9/7 12/21 7/7 0.377a   3/14 25/21 0.009a 
 F df Mean±SD  F df Mean±SD  
cells/L 
CD16+ 0.371 2, 59 53±68 48±29 62±70  0.011 1, 60 51±66 53±45 
CD16- 0.227 2, 59 369±145 397±141 386±106 2.165 1, 60 428±137 372±131 
Ratio CD16+/CD16- 0.313 2, 59 0.14±0.10 0.13±0.07 0.15±0.14 NS 1.076 1, 60 0.11±0.10 0.14±0.10 NS 
% cells 
CD16+ 0.160 2, 59 11.6±7.2 11.0±5.5 12.2±9.4  1.437 1, 60 9.7±6.9 12.0±6.7  
CD16- 0.160 2, 59 88.4±7.2 89.0±5.5 87.8±9.4  1.432 1, 60 90.3±6.9 88.0±6.7  
Ratio CD16+/CD16- 0.306 2, 59 0.14±0.10 0.13±0.08 0.15±0.14 NS 1.045 1, 60 0.11±0.10 0.14±0.10 NS 
FSC 
CD16+ 0.615 2, 59 570±59 556±71 544±53  0.005 1, 60 558±71 557±63  
CD16- 0.837 2, 59 571±60 555±67 540±55  0.064 1, 60 559±16 555±62  
Ratio CD16+/CD16- 0.257 2, 59 1.0±0.04 1.0±0.03 1.01±0.03 NS 0.755 1, 60 1.0±0.02 1.0±0.003 NS 
SSC 
CD16+ 0.784 2, 59 424±48 406±57 404±46  3.799 1, 60 431±58 402±49  
CD16- 0.938 2, 59 494±37 477±51 476±38  0.354 1, 60 487±46 479±45  
Ratio CD16+/CD16- 0.213 2, 59 0.86±0.07 0.85±0.05 0.84±0.04 NS 9.356 1, 60 0.88±0.06 0.84±0.05 0.003 
CD14 
CD16+ 0.226 2, 55 976±691 863±529 861±473  1.191 1, 60 1027±626 845±532  
CD16- 1.354 2, 58 2855±2055 2194±1331 2292±1161  0.299 1, 60 2116±332 2362±240  
Ratio CD16+/CD16- 1.051 2, 59 0.37±0.17 0.43±0.18 0.36±0.11 NS 6.003 1, 60 0.48±0.19 0.37±0.15 0.017 
CD36 
CD16+ 0.004 2, 59 315±194 316±120 320±110  0.060 1, 60 324±190 313±116  
CD16- 0.720 2, 59 755±196 713±221 790±175  1.926 1, 60 681±250 762±184  
Ratio CD16+/CD16- 1.191 2, 59 0.41±0.16 0.47±0.16 0.40±0.08 NS 2.544 1, 60 0.49±0.04 0.42±0.02 NS 
CD11b 
CD16+ 1.745 2, 27- 121±97 70±63 59±25  0.059 1, 28 87±63 80±76  
CD16- 3.817 2, 27 442±492 127±147 132±49  0.091 1, 28 184±181 222±72  
Ratio CD16+/CD16- 2.978 2, 27 0.44±0.22 0.71±0.36 0.45±0.11 NS 0.094 1, 28 0.62±0.22 0.58±0.08 NS 
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Table 4 Correlation between plasma level of adrenaline and CD16+ monocytes number and phenotype in 
central obesity. 
 
CD16+monocytes 
Number FSC SSC CD14 CD11b 
 ρ p ρ p ρ p ρ p ρ p 
Adrenaline 0.309 
0.044 0.488; 0.001 0.307 0.045 0.307 0.050 0.468 0.033 
Abbreviations: FSC, forward light scattered; SSC, sideward light scattered; The median fluorescence intensity of CD14, CD36 and 
CD11b was assessed in each subset and expressed as fluorescence arbitrary units. ρ, Spearman’s rho; p, level of significance. 
Significant correlations are in bold face. 
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Figure legends 
Figure 1 Gating strategy of the monocyte subsets- Total monocytes (red dots) were selected in the SSC vs. 
CD14 dot plot, based on the expression of CD14 (panel A). Afterwards, classical CD14+CD16- monocytes 
(green dots) and proinflammatory CD14+CD16+ monocytes (blue dots) were identified in the CD16 vs. 
CD14 dot plot, based on the expression of CD14 and CD16 (panel B). Subsequently, these two monocyte 
populations were gated and separately analyzed for the levels of CD11b, CD14 and CD36 expression, using 
the median fluorescence intensity obtained for each marker; the forward light scatter (FSC) and sideward light 
scatter (SSC) were also measured. Finally, the ratio between the values obtained on CD14+CD16+ and 
CD14+CD16- monocytes was calculated, for each parameter and in each individual. CD14 and CD16 
positivity were defined using fluorescence minus one controls. Other leukocytes are represented as gray dots. 
Dot plots showed in this figure were obtained using the Infinicyt software (Cytognos). 
 
Figure 2 Correlation between plasma levels of adrenaline and CD14 expression (A) and forward light 
scattered (FSC) (B) of CD16+ monocytes. Abbreviations: ρ, Correlation coefficients, calculated by 
Spearman test; p, level of significance.  
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Figure 2 
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Chapter 3: Paper 2- β2 Adrenoceptors are under expressed 
in Peripheral Blood Mononuclear Cells and associate with a 
better metabolic profile in Central Obesity. 
 
3.1 Preface to Paper 2 
In this paper, we present the study of the expression of adrenergic receptors (AR) on 
peripheral mononuclear cells in human obesity-related subclinical inflammatory state, 
based on the results of the manuscript 1 that suggested immunomodulation by adrenaline 
and noradrenaline in this condition. First, we performed a pilot experiment studying all 
adrenoceptors subtypes. β2-adrenoceptors (β2AR) were showed to be under expressed in 
subjects with central obesity. In view to explain the molecular results of the distinct 
adrenergic pattern in obesity, statistical analysis with multiple logistic regression was 
performed. Detailed results are described concerning the relationships between β2AR 
expression in peripheral immune cells and anthropometric, metabolic, endocrine and 
inflammatory parameters.  
 
3.2 Paper 2 
Leite F, Lima M, Marino F, Cosentino M, Ribeiro L. β2 Adrenoceptors are under expressed 
in Peripheral Blood Mononuclear Cells and associate with a better metabolic profile in 
Central Obesity. Accepted for publication in International Journal of Medical Sciences 
(manuscript nº 19638j).  
.  
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Abstract 
Background: Central obesity (CO) is an inflammatory disease. Because immune cells and 
adipocytes are catecholamines(CA)-producing cells, we studied the expression of 
adrenoceptors (AR) in peripheral blood mononuclear cells (PBMC) hypothesizing a distinct 
adrenergic pattern in inflammatory obesity. Methods: AR expression was assessed in blood 
donors categorized by waist circumference (WC) (CO: WC≥0.80 m in women and ≥0.94 m 
in men). Following a pilot study for all AR subtypes, we measured β2AR expression in 
fifty-seven individuals and correlated this result with anthropometric, metabolic and 
inflammatory parameters. A ratio (R) between AR mRNA of CO and non-CO <0.5 was 
considered under and >2.0 over expression. Results: The pilot study revealed no differences 
between groups, except for β2AR mRNA. CO individuals showed underexpression of β2AR 
relatively to those without CO (R=0.08; p=0.009). β2AR expression inversely correlated 
with triacylglycerol (r=-0.271; p=0.041), very low-density lipoprotein-cholesterol (r=-
0.313; p=0.018) and leptin (r=-0.392; p=0.012) and positively with high-density 
lipoprotein-cholesterol (r=0.310: p=0.045) plasma levels. Multiple logistic regression 
analysis showed a protective effect of β2AR expression (≥2x10-6) [odds ratio (OR) 0.177 
with respective confidence interval of 95% (95% CI) (0.040- 0.796)] for the occurrence of 
CO. A higher association was found for women as compared to men (9:1) [OR 8.972 
(95% CI) (1.679–47.949)]. Conclusion: PBMC β2AR, underexpressed in centrally obese, 
are associated with a better metabolic profile and showed a protective role for the 
development of CO. The discovery of β2AR as a new molecular marker of obesity 
subphenotypes in PBMC might contribute to clarify the adrenergic immunomodulation of 
inflammatory obesity. 
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Introduction 
Obesity, notably visceral or central, is a major risk factor for cardiovascular disease (CVD) 
increasing the incidence of hypertension, type 2 diabetes and dyslipidemia [1] which are 
linked to reduced life expectancy and premature death.  
Central adiposity, as measured by waist circumference (WC), is highly correlated with 
visceral fat, as measured by computed tomography [2]. Visceral obesity and its 
comorbidities are characterized by increased concentrations of a large panel of cytokines, 
chemokines and acute-phase proteins in circulation, which are in turn closely associated 
with low-grade chronic inflammation, although the pathophysiological mechanisms 
underlying this association are not completely understood [3]. 
Remarkably, immune cells, neurons and adipocytes share common signalling pathways. 
These pathways are mediated by the catecholamines (CA), adrenaline (AD) and 
noradrenaline (NA), through the activation of adrenoceptors (AR) [4, 5]. There are three 
major types of ARs (α1, α2, β), each of which is further divided into three subtypes. These 
receptors are involved in essential metabolic and central nervous system functions. There is 
ample evidence that AR, and more specifically adrenoceptor β2 (β2AR), have a role in 
immunomodulation. Endogenous CA produced by immune cells regulate, through 
autocrine/paracrine mechanisms, several immune cell functions [6], modulating 
inflammatory responses in monocytes and lymphocytes, among other immune cells, during 
health and disease [5, 6]. The global outcome of β2AR triggering in inflammation seems to 
be beneficial [6]. 
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In obesity, visceral adipose tissue (AT) becomes infiltrated by a large number of immune 
cells, namely, macrophages [7] and lymphocytes [8]. Most of these originate from 
circulating peripheral blood mononuclear cells (PBMC) [9]. These cells seem to possess the 
full cellular machinery for de novo synthesis, release, and inactivation of CA [6] and are 
referred as potential sources of biomarkers of early homeostatic imbalance that would be 
useful for the study and prevention of metabolic disorders as obesity [10]. Recent studies 
have reported that adipocytes are likewise capable of CA de novo synthesis suggesting a 
role of adipocyte CA in metabolic processes [11]. Our group demonstrated that CA release 
is differently affected by dietary unsaturated fatty acids [12]. 
Adrenergic modulation of immunity remains a non-appreciated issue in obesity. We 
recently described for the first time that tyrosine hydroxylase, the rate limiting step of CA 
synthesis, and dopamine receptors in PBMC are underexpressed in central obesity (CO) 
[13]. We hypothesize that the adrenergic signature is distinct under these conditions, 
because AD and NA, important metabolic and immune regulators, may mediate 
inflammatory obesity.  
In the present study, we looked for the expression of AR in circulatory immune cells and its 
correlation with anthropometric, endocrine/metabolic and inflammatory parameters in a 
well-defined group of blood donors (BD) to establish: i) whether central obesity, a 
surrogate marker of abdominal fat mass [14], is associated with variable AR expression in 
PBMC and ii) the extent to which this association is explained by anthropometric 
/metabolic/endocrine/inflammatory factors. 
This study may give rise to new therapeutic interventions to manage inflammatory central 
obesity and its co-morbidities. 
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Methods 
Participants and experimental design 
This study was conducted in 57 blood donors from the Blood Bank of Clinical 
Haematology Department of Centro Hospitalar of Porto (CHP), Portugal; it meets the 
standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 
1989, and 1996 [JAMA 1997;277:925-926], and was approved by the Ethical Committee and 
Research Office, and authorized by the administration board of CHP, being registered with the 
identifier 072/09 (047-DEFI/065-CES). All participants signed a written informed consent, after 
being ware about the objectives of the study and the confidentiality of the data. The individuals met 
the selection criteria for blood donation and were not under any medicines during the previous 
month. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 
twice and the mean values were calculated. The total sample was studied for 
anthropometric, metabolic/endocrine and inflammatory parameters and PBMC AR 
expression. The characteristics of the enrolled subjects are shown in Table 1.  
Anthropometrics 
Body mass index (BMI) was calculated by dividing weight by squared height, expressed in 
kg.m-2. BMI categories were defined according to the guidelines of the World Health 
Organization [15]. WC was measured at the level midway between the lowest rib and the 
iliac crest. Height (in m) was confirmed by medical record. The participants, all 
Caucasians, were divided in two groups, according to the International Diabetes Federation 
criteria of CO defined as WC ≥0.80 m in women and ≥0.94 m in men [16]. 
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Biochemical analysis 
Blood samples were taken from all subjects under standardized conditions. Fasting plasma 
glucose, triacylglycerol (TAG), total cholesterol (TC), high-density lipoprotein-cholesterol 
(HDL-C), low-density lipoprotein-cholesterol (LDL-C), and very low-density lipoprotein-
cholesterol (VLDL-C), were measured with turbidometry and spectrophotometry 
methodology using the Cobas® 8000 autoanalyzer (Roche, Rotkreuz, Switzerland). 
Glycosylated hemoglobin (HbA1c) measurements were done by High Performance Liquid 
Chromatography (HPLC), using the Hi-Auto A1c HA-8140 HPLC (Menarini Diagnostics, 
Florence, Italy).  Plasma cortisol was performed with an electrochemiluminescence 
immunoassay (Elecsys Systems analyser Roche, Roche Diagnostics International Ltd 
Rotkreuz, Switzerland) and leptin was measured in serum by solid phase two-site enzyme 
immunoassay (Merecodia Leptin ELISA, Mercodia AB, Sylveniusgatan 8A, Uppsala, 
Sweden). High-sensitivity C-reactive protein (hsCRP) (mg/L) determined by nephelometry 
(CardioPhase® hsCRP–BnProSpec Siemens Healthcare Diagnostics Inc. New York, United 
States) was categorized by the following cardiovascular event risk groups: <1- low, ≥1 to 
<3 –intermediate and above 3 - high risk, as described before [17]. 
Assay of monocytes by Flow Cytometry 
Monocytes from fresh EDTA-K3 anti-coagulated whole blood samples were determined by 
means of flow cytometry, as previously described [18]. Immunophenotypic studies were 
performed using a whole blood stain-lyse-and-then-wash method and a direct 
immunofluorescence technique with the following four-color panel of monoclonal 
antibodies: mouse anti-human CD36 conjugated with FITC (clone FA6.152, IgG1), mouse 
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anti-human CD16 conjugated with PE (clone 3G8, IgG1), mouse anti-human CD14 
conjugated with PE-Cy5 (IgG2a, clone RMO52) all obtained from Beckman Coulter 
(catalogue numbers IM0766U, IM1238U and IM2640U, respectively), and mouse anti-
human CD11b conjugated with APC (IgG2a, clone D12) obtained from Becton Dickinson 
(BD) (catalogue number 333143). 
Data acquisition was carried out on a FACS-Calibur flow cytometer (BD), using the Cell 
Quest software program (BD). A minimum of 2x105 events were used for each staining and 
stored as list mode data. The Paint-a-Gate Pro software program (BD) was used for data 
analysis. Monocytes were quantified based on CD14 expression. CD16 was used to 
differentiate classical (CD16-) and non-classical (“pro-inflammatory”) (CD16+) monocyte 
populations. The median fluorescence intensity (MFI) of CD14, CD36 and CD11b was 
assessed in each subset and expressed as fluorescence arbitrary units (AU). The forward 
light scatter (FSC) and sideward light scatter (SSC) of cell subsets were also determined. To 
overcome inter-individual variations and maturation process, in each subject, the ratio for 
each parameter between CD14+CD16+ non-classical monocytes and CD14+CD16- 
classical monocytes was calculated.  
Expression of AR in PBMC by Real time PCR 
Peripheral blood mononuclear cells were isolated by density gradient centrifugation (Ficoll 
method), as previously described [19]. Total RNA was extracted by PerfectPure™ RNA 
Cell & Tissue kit (5Prime), and the amount of extracted RNA was estimated by 
spectrophotometry at 260 nm. Total RNA was reverse transcribed using the High-capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, USA), according to the 
manufacturer’s instructions. Real-time PCR was performed with an ABI prism 7000 
124 
 
apparatus (Applied Biosystems) using the Assay on demand kits for the genes of interest 
(Applied Biosystems), according to the manufacturer’s instructions. Gene sequence data 
were obtained from the Reference Sequence collection (RefSeq; 
www.ncbi.nlm.nih.gov/projects/RefSeq). For each gene, the thermal profile was as follows: 
stage 1, 2 min at 50°C; stage 2, 10 min at 95°C; stage 3, 40 cycles including 15s at 95°C 
and 1 min at 60°C. Table 2 contains the details about real-time PCR conditions.  
Linearity of real-time PCR assays were tested by constructing standard curves by use of 
serial 2-fold dilutions of a standard calibrator cDNA and regression coefficients (r2) were 
always >0.900 (data not shown). Relative expression was determined by normalization to 
18S rRNA (housekeeping gene) by means of AB Prism 7000 SDS software™. Gene 
expression levels in a given sample were represented as 2-∆Ct where ∆Ct = [Ct(gene)–Ct 
(18S rRNA)]. 
We performed a pilot study of all AR subtypes expression in 15 individuals divided in two 
groups: with and without CO, representing the lowest and the highest BMI of the total 
sample in order to know which AR subtype(s) showed the highest differences between the 
opposite fat groups (in Table 3). The ratio (R) was calculated between AR mRNA 
expression between individuals with and without CO. R <0.5 was considered under and 
>2.0 over expression. Our technical variance in that set of experiments is 0.03 cycles² for 
all adrenoceptor gene expression (so the standard deviation, SD is 0.17 cycles); also 
consider that we measure samples in triplicates, so standard error (SE) for the mean ct is SE 
= sqrt (0.03/3) = sqrta (0.01). By error propagation, the SE of a mean difference (delta-ct) is 
sqrt (2*0.01) and the SE for a difference of such differences (delta-delta-ct) is sqrt 
(2*2*0.01) = sqrt (0.04) = 0.2. This SE is determined on 2*(3-1) = 4 degrees of freedom, so 
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the 95% confidence interval has a half width of t[0.025;4]*0.2 = 2.77*0.2 = 0.554 or 
roughly half cycle. The total width of the interval is thus 1 cycle. This means that a 2-fold 
difference (Δct=1) is considerably larger than the 95% CI obtained without any biological 
variance when 3 replicates are measured. For this reason, only differences exceeding 1 
cycle were thereafter considered.  
Statistical analysis 
The modified Kolmogorov-Smirnov test with the correction of Lilliefors was used to 
evaluate the fit of the data to a normal distribution. Unless otherwise indicated, variables 
were presented using relative and absolute frequencies, means ± standard error of the mean 
(SEM). Non-normal distributed data was presented as median, 25th and 75th percentiles. To 
compare the quantitative independent variables, we used bivariate statistical analysis 
ANOVA or non-parametric tests Mann-Whitney (comparison between 2 groups) or 
Kruskal–Wallis (comparison of more than 2 groups) tests for normal and non-normal 
distributed data, respectively. The Pearson Chi-Square test was used to compare qualitative 
independent variables. Correlations were assessed by Pearson test to determine the 
relationship between normal distributed quantitative variables and by non-parametric 
Spearman rank analysis for non-normal distributed quantitative data. The strength of 
association between variables was estimated by odds ratio (OR) and their respective 
confidence interval of 95% (95% CI) using multiple logistic regression. Variables that in 
the univariate analysis showed statistical significance below 10% (p <0.10) were included 
in the logistic regression model. Data analysis was performed using the SPSS version 22.0 
(SPSS, Chicago, IL, USA). P-value lower than 0.05 was considered statistically significant. 
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Results 
Characteristics of the study participants  
The BD, with mean age of 40 years (minimum 20 and maximum 63), showed a prevalence 
of CO of 71.9%. Twenty-five individuals were female (44%) with a higher percentage of 
CO compared with men, respectively 92 % vs 56% (p=0.006). The total group presented a 
median hsCRP level, reflecting an intermediate cardiovascular risk, low median plasma 
leptin levels and mean SBP values of systolic hypertension. The other metabolic/endocrine 
parameters were within the normal range (Table 1).  
Anthropometric and metabolic/endocrine parameters 
The CO group showed higher leptin, TC and VLDL-C values in comparison with the group 
without CO (Table 4). WC was correlated with leptin (r=0.524; p=0.001), VLDL-C 
(r=0.391, p=0.003) and TAG (r=0.319, p=0.016) plasma levels. In CO, as well in all 
population, WC was correlated with SBP (r=0.495, p=0.001); (r=0.385, p=0.003), 
respectively and with DBP (0.477, p=0.001); (r=0.493, p<0.001), respectively. In both 
total and CO groups, AD was associated with VLDL-C (r=0.336, p=0.011); (r=0.455, 
p=0.002), respectively and with TAG plasma levels (r=0.323, p=0.014); (r=0.428, 
p=0.005), respectively, and in CO was found to be inversely correlated with HDL-C (r=-
0.346; p=0.025).In both total and CO groups, we also found significant correlations 
between NA and TC (r=0.277, p=0.037); (r=0.344, p=0.026), respectivelyand with LDL-
C (r=0.301, p=0.023); (r=0.354, p=0.022), respectively 
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Monocytes subsets and hsCRP 
The total sample showed a mean of 440±22 monocytes/L (7.1 ± 0.4% of total leucocytes), 
of which 390 ± 19 cells/L (89 ± 0.9% of all monocytes) were CD16- and 50 ± 7 cells/L 
were CD16+ monocytes (11± 0.9% of all monocytes). Neither the number (Table 5) nor the 
percentage of CD16+ (11.5±0.9% vs 9.9±1.9%; p=0.410) and of CD16- monocytes 
(89±0.9% vs 90±1.9%; p=0.408) were different between groups with and without CO, 
respectively. However, the ratio between non-classical CD16+ and classical CD16- 
monocytes, calculated to overcome inter-individual variations, showed differences between 
these two groups. In particular, centrally obese showed lower CD14 and SSC ratios 
comparatively to non-CO subjects, reflecting a more inflammatory phenotype pattern of 
non-classical monocytes (Table 5). Despite hsCRP plasma levels were similar between CO 
and non-CO groups, in centrally obese hsCRP was correlated with leptin values (r=0.397, 
p=0.011). In addition, plasma levels of leptin were significantly different when comparing 
the hsCRP cardiovascular risk groups (p=0.011): the high-risk group 3.100 (0.800-5.170) 
mg/L showed higher levels of leptin relatively to the intermediate 0.615 (0.480- 1.140) 
mg/L and to the low risk groups 0.320 (0.100- 0.850) mg/L. The number of CD16+ 
monocytes was correlated with hsCRP (r=0.372; p=0.005) and with NA plasmatic level 
(r=0.341; p=0.01).  
AR expression in PBMC  
The pilot study considered PBMC expression of all the 9 AR in a subgroup of subjects with 
and without CO selected as those having the highest or the lowest BMI values (Table 3). 
Results from the pilot study revealed that there were no differences between groups except 
for β2AR mRNA levels. Indeed, the expression of β2AR in subjects with CO was less than 
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half in comparison to those without CO. This finding led us to study β2AR expression in a 
larger number of subjects.  
We have found lower expression of β2AR in the CO group in comparison to the group 
without CO (R=0.08; p=0.009) (Fig. 1). In the CO model, the logistic regression analysis 
demonstrated a lower association for the development of CO for β2AR mRNA expression 
≥2x10-6odds ratio (OR) 0.177 with respective confidence interval of 95% (95% CI) (0.040- 
0.796) and a higher association for women, relatively to men [9:1OR 8.972 (95% CI) 
(1.679 – 47.949)]. 
To evaluate the clinical relevance of decreased expression of β2AR, we correlated β2AR 
mRNA levels with metabolic/endocrine parameters. When considering all the individuals, 
the expression of β2AR in PBMC inversely correlated with VLDL-C (r=-0.313; p=0.018), 
TAG (r=-0.271; p=0.041) and leptin (r=-0.392; p=0.012), whereas in CO it was correlated 
with plasmatic HDL-C (r=0.310: p=0.045). After adjusting for gender, β2AR mRNA 
correlated with HDL-C (r=0.298: p=0.026) and inversely with VLDL-C (r=-0.361; 
p=0.006) and TAG plasmatic levels (r=-0.311; p=0.020). 
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Discussion 
Our study addressed for the first time the expression of adrenoceptors in PBMC in sub-
clinical inflammatory obesity. The main findings are fourfold. First, in central obesity, 
associated with inflammation, as shown by higher plasma levels of leptin and a more 
inflammatory pattern of monocytes, PBMC under express β2AR in comparison to PBMC 
from non-CO subjects. Second, β2AR expression was inversely correlated with a 
dyslipidemic lipid profile and with leptin plasma levels. Third, the multiple logistic 
regression analysis showed a lower and higher association, respectively for β2AR 
expression (≥2x10-6) and female for the occurrence of CO. Fourth, our work suggests a 
protective role of β2AR expression in immune cells as well as adrenergic 
immunomodulation of inflammatory obesity. 
β2ARs are the most expressed ARs on immune cells and considered the main mediators of 
CA immune effects; their activation usually results in anti-inflammatory effects [6, 20, 21]. 
Indeed, stimulation of β2AR modulates cytokine production by activated innate immune 
cells, primarily inhibiting some proinflammatory cytokines, such as TNF-α, IL-12 and IL-6, 
and by increasing IL-10 and IL-33 release by these cells 22- 24. 
The PBMC underexpression of β2AR in CO may have resulted, through mechanisms as 
desensitization and down-regulation, from the action of circulating or endogenously 
produced CA, leptin and other cytokines and lipids. Indeed, apart from circulating CA, with 
similar values in subjects with and without CO, several of these molecules are elevated in 
this condition [25]. Our findings are in line with a decreased number of β2AR in PBMC in 
inflammatory immune mediated diseases such as systemic lupus erythematosus [26], 
multiple sclerosis [27], rheumatoid arthritis (RA) [26], juvenile RA [28], Crohn’s disease 
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[29] and myasthenia gravis [30]. Critical heart disease, a chronic low-intensity 
inflammation condition, was also associated with reduced β-AR on lymphocytes due to a 
non-regulated increased release of proinflammatory cytokines [31]. 
An important point for discussion is whether the altered pattern of β2AR and monocytes 
observed in an early phase of CO is a cause or consequence of inflammatory obesity. 
Further studies are needed to elucidate this association. Nonetheless, some findings support 
a role of circulating leptin and lipids in the association between visceral fat and PBMC 
β2AR expression: a) centrally obese present higher plasma levels of leptin, TC and VLDL-
C and a more inflammatory pattern of monocytes comparing to those without CO and b) 
β2AR expression inversely correlated with plasma TAG, VLDL-C and leptin and positively 
with HDL-C plasma levels.  
Cellular lipid homeostasis can indeed influence the level and function of immune cells [32]. 
Remarkably, Devêvre et al. (2015) [33] recently described that HDL-C negatively 
correlated with molecules involved in chemotaxis, proposing that decreased HDL could 
therefore be directly linked to changes in monocyte phenotype and function. This is 
consistent with our findings, since in centrally obese HDL-C levels were positively related 
with β2AR mRNA and inversely with AD. On the other hand, NA, an independent factor 
for the development of metabolic syndrome [34], correlated not only with TC and LDL-C, 
but also with the number of “pro-inflammatory monocytes” and hsCRP, findings that 
corroborate a putative role in inflammation [35]. 
β2ARs have been pointed out as a promising target in the pharmacotherapy of Multiple 
Sclerosis (MS) [36]. In MS patients, β2AR expression in lymphocytes increases after 
treatment with beta-interferon [37]. It would be interesting to see if during weight loss there 
is an increase of β2AR expression in immune cells.  
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Down regulation of AR-mRNA may also occur as a result of the effects of inflammatory 
cytokines produced by immune cells in response to fatty acids binding to toll-like receptor 
4 (TLR 4) [38]. 
Leptin, besides its main role in metabolism, is also an immune mediator, promoting the 
activation, chemotaxis and survival of both innate and adaptive immune cells [39]. As 
stated before, β2AR mRNA inversely correlated with leptin plasma levels, and leptin 
receptors, found in monocytes and lymphocytes [40] mediate the production of 
proinflammatory cytokines by these cells [39]. Interestingly, a deficiency of leptin receptor 
has been described as leading to a decreased expression of proinflammatory cytokines as 
tumour necrosis factor α (TNF-α), interleukin 6 (IL-6) and C-C motif chemokine ligand 2 
(CCL2) and decreased infiltration of macrophages [41]. In centrally obese, leptin plasma 
values were also correlated with the hsCRP, also synthesized by adipocytes [42] and 
likewise described as able to affect β2AR function [43]. 
As previously highlighted [44], because intra-abdominal fat is not readily available for 
clinical assessment, and AT-infiltrating immune cells are originated from bone marrow, 
circulatory immune cells could serve as markers of intra-abdominal fat inflammation and 
ultimately of obesity associated cardio-metabolic risk. The present work identifies one 
more molecular marker of obesity subphenotypes and contributes to the continued search 
necessary for their better definition. 
β2AR underexpression could be considered as a molecular signature of PBMC in obese 
patients. Indeed, modified mRNA expression of several genes involved in cytokines 
production, chemotaxis, fatty acid storage and glucose metabolism and pathogen 
recognition, was already related to monocyte function in obesity [33]. 
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Our hypothesis is that proinflammatory monocytes (here also characterized by low cellular 
complexity (low SSC) and CD14 ratios [13] and underexpressing β2AR) of centrally obese 
would sense metabolic/inflammatory circulating factors. In response, these cells secrete 
more inflammatory cytokines and are probable more prone to migrate into AT where they 
could differentiate into macrophages. Both processes perpetuate a vicious cycle of 
inflammatory cell recruitment and secretion of deleterious adipokines and free fatty acids 
by AT that predispose to metabolic dysfunction. 
The current study has some limitations that merit comment. β2AR expression was evaluated 
in PBMC as a population. In future studies, it would be valuable to investigate possible 
differential expression on distinct mononuclear cell subsets (e.g. lymphocytes vs 
monocytes, T helper (TH) 1 vs Th2, regulatory T cells vs Th17). Furthermore, we only 
studied mRNA levels of β2AR and it would be relevant to also measure its protein level. 
Even though, Guereshi et al. (2013) [45] found that β2AR mRNA levels were higher in 
naıve T cells than in Treg cells and protein expression confirmed the results for β2AR 
transcripts. Our group also showed in human lymphocytes that dopaminergic receptors 
responsiveness is better predicted by mRNA rather than membrane receptor expression 
[46]. 
 
Conclusion 
Association of CO with a higher activation of innate immune response and a lower β2-
adrenoceptor expression suggests that circulating peripheral mononuclear immune cells 
sense inflammatory obesity, with β2AR expression being less associated with the 
occurrence of CO.  
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An important challenge now is to understand how this receptor functions on PBMC in 
inflammation related to obesity before we can truly apply this knowledge in a rational 
manner in clinical conditions. In this sense, evaluation of β2-AR agonists as potential anti-
inflammatory drugs is strongly warranted. Functional studies should be also planned in the 
near future to determine the migratory and inflammatory functions of these circulatory 
cells.  
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Table 1 Characteristics of the study participants (n=57) 
 
Parameter Unit Reference values (range) mean± SEM/ Min- Max 
Age Years  40±2 20-63 
Weight Kg  77±2 51-120 
Height M  1.67±0.01 1.50-1.87 
BMI Kgm-2  27.6±0.6 19.6-40.1 
WC M  0.97±0.02 0.75-1.24 
SBP MmHg <130 134±2 103-177 
DBP mmHg <85 80±1 61-107 
Glycemia mg/dL 70 - 105 85±1 67-115 
HbA1c % 3.8 - 5.6 5.2±0.1 4.5-5.8 
TC mg/dL 0 - 200 194±5 117-283 
LDL-C mg/dL 0 - 130 123±4 60-209 
HDL-C mg/dL 35 - 55 50±2 25-91 
VLDL-C mg/dL 3 - 56 21±2 6-58 
TAG mg/dL 40 - 160 109±10 32-475 
hsCRP mg/L 
< 1.0 low risk 
1.0 <3.0 intermediate risk 
>3.0 high risk 
1.38 (0.66- 3.01) 0.0-17.8 
Noradrenaline pmol/L 709 - 4019 684 (395-1552) 40-3760 
Adrenaline pmol/L <328 151 (81-225) 55-473 
Cortisol g/dL 6.2 – 19.4 15.0 (12.6-17.3) 6.4-28.4 
Leptin ng/mL 2.0 – 5.6 0.615 (0.245-1.075) 0.003-5.300 
Leucocytes cells/L 4500 - 13000 6432±216 3500-11600 
Monocytes cells/L 400 - 500 440±22 82-964 
Lymphocytes cells/L 1000-4800 1898 (1538-2299) 1007-5069 
Abbreviations: BMI, Body Mass Index; WC, waist circumference; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; HbA1c, glycosylated hemoglobin; TC, total cholesterol; LDL-C, low-density 
lipoprotein cholesterol; HDL-C, high-density lipoprotein-cholesterol; VLDL-C, very low-density lipoprotein-
cholesterol; TAG, triacylglycerol; hsCRP, high-sensitivity C reactive protein; Min, minimum; Max, 
maximum. Data are presented as mean ± standard error of the mean (SEM), unless otherwise indicated by 
corresponding to data presented as median, 25th and 75th percentiles. 
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Table 2 Real-Time PCR gene expression 
 
 
Gene  
Symbol 
UniGene 
ID 
Interrogated  
Sequence 
RefSeq/GenBank mRNA 
Translated 
protein 
 
Exon boundary 
RefSeq/GenBank 
mRNA 
Assay location 
RefSeq/GenBank 
mRNA 
Amplicon 
length 
Annealing 
temperature 
(°C) 
Efficiency 
(%) 
α1A-AR Hs. 709175 NM_033302.2 
NP_150645.
2 
1-2 1324 112 60 99.98 
α1B-AR Hs. 368632 NM_000679.3 
NP_000670.
1 
1-2 1126 61 60 100.04 
α1D-AR Hs. 557 NM_000678.3 
NP_000669.
1 
1-2 1166 68 60 100.08 
α2A-AR Hs. 249159 NM_000681.3 
NP_000672.
3 
1-1 1960 116 60 101.00 
α2B-AR Hs. 247686 NM_000682.5 
NP_000673.
2 
1-1 823 117 60 100.05 
α2C-AR Hs. 123022 NM_000683.3 
NP_000674.
2 
1-1 646 93 60 99.08 
β1-AR Hs. 99913 NM_000684.2 
NP_000675.
1 
1-1 863 79 60 99.00 
β2-AR Hs. 2551 NM_000024.5 
NP_000015.
1 
1-1 778 65 60 100.02 
β3-AR Hs. 2549 NM_000025.2 
NP_000016.
1 
1-2 1401 65 60 99.87 
18S 
rRNA 
X03205.1 N.A. N.A. N.A. N.A. 187 60 98.80 
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Table 3 Pilot study on peripheral blood mononuclear cells adrenoceptor mRNA expression 
 
Central obesity 
p Ratio Yes/No No Yes 
n 5 10   
F/M 2/3 8/2 0.12  
Age 31 ± 3 40 ± 3 0.10  
BMI 21.1 ± 0.7 30.1 ± 2.4 0.02  
AR subtype 
α1A 6.95 x 10-9  ± 1.45 x 10-9- 6.87 x 10-9  ± 4.63 x 10-10  0.99 
α1B 1.11 x 10-7  ± 2.02 x 10-8 ; 1.56 x 10-7 ± 3.66 x 10-8  1.41 
α1D 7.76 x 10-6  ± 2.09 x 10-6 1.1 x 10-5 ± 2.21 x 10-6  1.42 
α2A 3.72 x 10-9  ± 2.89 x 10-9 5.74 x 10-9  ± 1.47 x10-9  1.54 
α2B not detected not detected   
α2C 4.39x10-9  ± 6.76x10-10 4.57x10-9  ± 3.69x10-10  1.04 
β1 not detected not detected   
β2 7.54 x10-5 ± 5.98x10-5 3.14x10-5  ± 1.84x10-5  0.42 
β3 2.56 x10-8 ± 5.51x10-9 2.13x10-8  ± 5.51x10-9  0.83 
Analysis of AR mRNA expression in peripheral blood mononuclear cells in a subgroup of subjects without and 
with central obesity selected as those having highest or lowest BMI values. Data are presented as mean  
standard error of the mean (SEM). F/M, female male ratio; BMI, body mass index; AR, adrenoceptor. For 
details see Methods. 
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Table 4 Comparison of anthropometric, metabolic/endocrine parameters between 
groups with and without central obesity (n=57) 
 
Factor F df 
Mean ± S.E.M. 
p 
CO No CO 
F/M (n) 8.596 1, 55 23/19* 2/13* 0.006 
Age (years) 8.640 1, 55 42 ± 2 37 ± 3 0.194 
Weight (Kg) 3.077 1, 55 79 ± 2 72 ± 3 0.085 
Height (m) 5.699 1, 55 1.65 ± 0.01 1.71 ± 0.01 0.020 
BMI (Kgm-2) 14.126 1, 55 28.7 ± 0.6 24.4 ± 0.7 <0.001 
WC (m) 26.869 1, 55 1.00 ± 0.016 0.86 ± 0.016 <0.001 
SBP (mmHg) 0.000 1, 55 134 ± 2 134 ± 4 0.983 
DBP (mmHg) 2.606 1, 55 82 ± 2 77 ± 2 0.112 
Glycemia (mg/dL) 0.114 1, 55 85 ± 1 86 ± 1 0.737 
HgA1c (%) 1.386 1,55 5.1 ± 0.1 5.2 ± 0 0.244 
TC (mg/dL) 4.131 1, 55 200 ± 5 178 ± 9 0.047 
LDL-C (mg/dL) 2.420 1, 55 127 ± 5 112 ± 8 0.126 
HDL-C (mg/dL) 0.065 1, 55 50± 2 51 ± 4 0.800 
VLDL-C (mg/dL) 4.596 1, 55 23 ± 2 16 ± 2 0.036 
TAG (mg/dL) 3.726 1, 55 120 ± 12 79 ± 8 0.059 
NA (pmol/L) 2.136 1, 55 1054 ± 129 706± 168 0.150 
AD (pmol/L) 0.198 1, 55 167 ± 15 181 ± 30 0.658 
Cortisol (g/dL) 0.024 1, 55 15 ± 0.9 15 ± 1.0 0.877 
Leptin (ng/mL) 8.116 1, 38 1.30 ± 0.25 0.15 ± 0.05 0.007 
Abbreviations: CO, central obesity; BMI, body mass index; WC, waist circumference; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; TAG, triacylglycerol; 
TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-
cholesterol; VLDL-C, very low-density lipoprotein-cholesterol; NA, noradrenaline; AD, adrenaline. 
F/M, female/male ratio; F, Snedcor’s distribution; df degree of freedom; p, level of significance. 
*Pearson Chi-Square test was applied for the comparison of 2 categorical variables. Data are 
presented as mean ± standard error of the mean (SEM). 
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Table 5 Comparison of the inflammatory markers hsCRP and monocyte subsets (counting 
and phenotype) between groups with and without central obesity (n=57) 
 
 No CO CO  
  F df Mean ± SEM/  Mean ± SEM/  p 
hsCRP

 (mg/L)  - - 
0.757  
(0.469-2.090) 
1.530 
(0.764-3.560) 
0.160 
Monocyte subsets 
cells/L 
CD16+ 0.055 1, 54 53±18 49±6 0.816 
CD16- 1.747 1, 54 431±38 375±21 0.192 
Ratio number 0.404 1, 54 0.12±0.03 0.13±0.01 0.528 
FSC 
CD16+ 0.227 1, 54 547±17 556±10 0.636 
CD16- 0.080 1, 54 549±17 554±10 0.778 
Ratio FSC 0.833 1, 54 1±0.01 1±0.01 0.365 
SSC 
CD16+ 3.998 1, 54 431±16 400±8 0.051 
CD16- 0.371 1, 54 485±13 477±7 0.545 
Ratio SSC 9.684 1, 54 0.89±0.01 0.84±0.01 0.003 
CD14 
CD16+ 0.285 1, 50 968±167 867±93 0.596 
CD16- 1.292 1, 53 1865±326 2423±264 0.261 
Ratio CD14  8.974 1, 54 0.50±0.05 0.36±0.02 0.004 
CD36 
CD16+ 0.108 1, 54 327±52 313±18 0.743 
CD16- 2.330 1, 54 670±68 765±28 0.133 
Ratio CD36  3.826 1, 54 0.50±0.04 0.42±0.02 0.056 
CD11b 
CD16+ 0.000 1, 24 80±30 81±18 0.996 
CD16- 0.621 1, 24 125±48 241±78 0.438 
Ratio CD11b  2.311 1, 24 0.69±0.07 0.51±0.06 0.141 
Abbreviations: CO, central obesity; FSC, forward scatter; SSC, side scatter; Values of CD14, CD36 and CD11b expressed as 
fluorescence arbitrary units (AU); Ratio SSC, ratio between side scatter (SSC) of CD16+monocytes and SSC of CD16- 
monocytes in each individual; Ratio CD14, ratio between the expression of CD14 on CD16+monocytes and the expression of 
CD14 on CD16- monocytes in each individual; Ratio CD11b, ratio between the expression of CD11b on CD16+monocytes 
and the expression of CD11b on CD16- monocytes in each individual; Data are presented as mean  standard error of the 
mean (SEM); F, Snedcor’s distribution; df, degree of freedom; p, level of significance. Data presented as median (25th-75th 
percentiles) and Mann-Whitney test used for comparison between the two groups. 
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Comparison of β2 Adrenoceptors expression in peripheral blood mononuclear cells between 
groups without and with Central Obesity 
 
 
Figure 1 Levels of β2-AR mRNA in PBMC from individuals with and without Central Obesity. Boxes 
indicate medians with 25th–75th percentiles and whiskers indicate minimum and maximum values.Mann-
Whitney test was used for comparison between the two groups. Abbreviations: CO, Central Obesity; non- CO, 
without CO; P, level of significance.  
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Chapter 4: Paper 3- Dopaminergic Receptors and Tyrosine 
Hydroxylase expression in Peripheral Blood Mononuclear 
Cells: a distinct pattern in Central Obesity. 
 
4.1 Preface to Paper 3 
While several lines of evidence support the involvement of DA in obesity through its role in 
the central nervous system no information exists so far regarding dopaminergic pathways in 
peripheral immune cells of obese subjects. We therefore decided to study the expression of 
dopaminergic receptors and tyrosine hydroxylase, the rate-limiting enzyme in the synthesis 
of DA, in PBMC from blood donors and their relationship with anthropometric, metabolic 
and inflammatory parameters in CO. The expression of DR D2 showed a protective role for 
the development of CO. We discuss a role for dopaminergic pathways in the crosstalk 
between immunity and metabolism and whether DR expressed on immune cells could 
represent pharmacological targets in obesity for better metabolic outcome. 
 
4.2 Paper 3 
Leite F, Lima M, Marino F, Cosentino M, Ribeiro L. Dopaminergic Receptors and Tyrosine 
Hydroxylase Expression in Peripheral Blood Mononuclear Cells: A Distinct Pattern in 
Central Obesity. PLoS ONE 2016;11: e0147483. doi: 10.1371/journal.pone.0147483. 
eCollection 2016. 
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Abstract 
 
Background: Dopamine (DA) may be involved in central obesity (CO), an inflammatory 
condition, through its role in the central nervous system and in periphery, where it may 
affect immune cell function through five different DA receptors (DR). Whether 
dopaminergic pathways in peripheral immune cells are implicated in the inflammatory 
condition linked to CO is however unknown. 
Methods: In a cohort of blood donors with and without CO, categorized by waist 
circumference (WC) (CO: WC ≥0.80 m in women and ≥0.94 /m in men), we studied the 
expression of DR and tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis 
of DA, in peripheral blood mononuclear cells (PBMC) and their relation with 
anthropometric and metabolic/endocrine and inflammatory parameters. DR D1-5 and TH 
expression was assessed by semi quantitative real-time PCR. As inflammatory markers, we 
investigated the immunophenotype of monocyte subsets by flow cytometry, staining for 
CD14, CD16, CD11b and CD36. 
Results: CO individuals showed higher plasma levels of leptin and higher inflammatory 
pattern of monocytes compared with non-CO. PBMC expression of DR D2, DR D4 and DR 
D5 as well as of TH were lower in CO in comparison with non-CO. DR D2, and DR D5 
expression correlated with lower WC and weight, and with lower inflammatory pattern of 
monocytes, and TH expression correlated with lower WC. DR D4 expression correlated with 
lower plasma levels of glycosylated hemoglobin, and DR D2 expression correlated with 
lower CO. 
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Conclusions: Results show that CO is associated with peripheral inflammation and 
downregulation of dopaminergic pathways in PBMC, possibly suggesting DR expressed on 
immune cells as pharmacological targets in obesity for better metabolic outcome. 
 
Keywords: central obesity, dopamine, dopaminergic receptors, immune cells 
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Introduction 
 
The modern obesity epidemic is a major public health issue, with the principal cause of 
morbidity due to metabolic dysfunction such as insulin resistance, type 2 diabetes, 
dyslipidemia and cardiovascular disease (1). Although it is widely accepted that a state of 
chronic low-grade inflammation is responsible for the metabolic dysfunction of obesity, its 
precise etiology is not completely characterized. 
The expression of common receptors and signaling networks in immune cells and 
adipocytes is the basis of the immunological metabolic cross-talk that explains the 
inflammatory comorbidities of obesity (2). On the one hand, immune cells play a central role 
in adipose tissue biology and, on the other hand, adipocytes have been recently proposed as 
“immune cells” since they express, cytokines, chemokines, multiple receptors and cell 
molecules involved in the immune response (3). Visceral or central obesity (CO) is indeed 
regarded as an inflammatory disease (1), and recent research has been focused on the study 
of peripheral blood mononuclear cells (PBMC) in obesity. Indeed, PBMC are exposed to 
systemic factors, such nutrients and inflammatory molecules (4), and may constitute 
potential biomarkers of early homeostatic energy imbalance, and reducing inflammation 
could be useful in preventing the occurrence of obesity and its consequences (5). 
Dopamine (DA), a classical brain neurotransmitter involved in various vital central nervous 
system functions, including feeding, reward and cognition, has been reported to modulate 
peripheral immune function (6–8). Indeed, DA-induced immunomodulation is currently the 
focus of intense experimental research and dopaminergic pathways are increasingly 
considered a target for drug development in immune disease (9). Immune cells themselves 
produce endogenous DA, and possibly uptake DA from other sources, using this transmitter 
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as an autocrine/ paracrine mediator (10–12). The first and rate limiting step of DA 
biosynthesis is the hydroxylation of the L-tyrosine to L-DOPA via tyrosine hydroxylase 
(TH). Once released, DA can bind to five distinct G protein-coupled receptors (13). 
Dopaminergic receptors (DR) are grouped into two families according to their 
pharmacological profile and main second messenger coupling: the D1-like (D1 and D5) 
which activate adenylate cyclase and the D2-like (D2, D3 and D4) which inhibit adenylate 
cyclase (13). 
While several lines of evidence support the involvement of DA in obesity through its role in 
the central nervous system (CNS) (14–16) no information exists so far regarding 
dopaminergic pathways in peripheral immune cells of obese subjects. We therefore decided 
to study the expression of DR and TH in PBMC from a cohort of blood donors and their rel 
ation with anthropometric, metabolic and inflammatory parameters in central obesity. 
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Methods 
Ethics statement 
This work was approved by the Ethical Committee of Centro Hospitalar of Porto (Porto, 
Portugal). All participants signed a written informed consent as described in the consent 
procedure of the study protocol approved by the Ethics committee. The clinical study is 
registered at the local research department with the identifier 072/09 (047-DEFI/065-CES). 
 
Study Population 
Thirty blood donors from the blood bank of Clinical Haematology department of Centro 
Hospitalar of Porto were enrolled in the study. The individuals followed the selection criteria 
for blood donation and were not under any medicines for at least one month before 
enrolment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 
twice and the mean values were used in the analyses; readings were taken on the right arm, 
with subjects in the supine position after they had rested for 5 min. 
 
Anthropometrics 
Height (in m) was based on an identification document and confirmed by medical record. 
Body weight was measured to the nearest 100 g on electronic weight scales. Body mass 
index (BMI) was calculated by dividing weight by height squared and expressed in kg x m-2 
and categorized as described before (17). Waist circumference (WC) was measured with a 
flexible tape at the level midway between the lowest rib and the iliac crest. CO was defined 
following International Diabetes Federation criteria by using WC (≥0.80m for women and 
≥0.94m for men) (18).  
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Biochemical analysis 
Blood samples were taken under standardized conditions. Fasting plasma glucose, 
triacylglycerol (TAG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), 
low-density lipoprotein-cholesterol (LDL-C), very low-density lipoprotein-cholesterol 
(VLDL-C), glycosylated hemoglobin (HbA1c) were measured using standard techniques. 
Plasma catecholamines (CA) [adrenaline (AD) and noradrenaline (NA) were assayed by 
high pressure liquid chromatography with electrochemical detection (HPLC-ED) 
(CROMSYSTEMS). Leptin was measured in serum by solid phase two-site enzyme 
immunoassay (Merecodia Leptin ELISA) and high-sensitivity C-reactive protein (hsCRP) 
by nephelometry (CardioPhase® hsCRP – BnProSpec Siemens).  
 
Flow Cytometry assay of monocytes 
Monocytes were analyzed in whole blood samples by means of flow cytometry following a 
previously described technique (19). The enumeration and the immunophenotypic analysis 
of monocytes were performed in fresh EDTA-K3 anti-coagulated blood samples. 
Immunophenotypic studies were done using a whole blood stain-lyse-and-then-wash method 
and a direct immunofluorescence technique using the following four-color panel of 
monoclonal antibodies: mouse anti-human CD36 conjugated with FITC (clone FA6.152, 
IgG1), mouse anti-human CD16 conjugated with PE (clone 3G8, IgG1), mouse anti-human 
CD14 conjugated with PE-Cy5 (IgG2a, clone RMO52) all obtained from Beckman Coulter 
(catalogue numbers IM0766U, IM1238U and IM2640U, respectively), and mouse anti-
human CD11b conjugated with APC (IgG2a, clone D12) obtained from Becton Dickinson 
(BD) (catalogue number 333143). 
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Data acquisition was carried out on a FACS-Calibur flow cytometer (BD), using the Cell 
Quest software program (BD). Information on a minimum of 2x105 events was acquired for 
each staining and stored as list mode data. For data analysis, the Paint-a-Gate Pro software 
program (BD) was used. Monocytes were quantified based on the CD14 expression, while 
CD16 was used to differentiate classical (CD16-) and non-classical (CD16+) monocyte 
populations. The median fluorescence intensity (MFI) of CD14, CD36 and CD11b was 
assessed in each subset and expressed as fluorescence arbitrary units (AU). The forward 
scatter (FSC) and side scatter (SSC) of the cell subsets were also measured. In order to 
overcome inter-individual variations, we calculated the ratio for each parameter between 
non-classical CD14+CD16+ and classical CD14+CD16- monocytes in each individual.  
 
Real time PCR analysis for the expression of DR and TH in PBMC 
Peripheral blood mononuclear cells were isolated by density gradient centrifugation (Ficoll 
method) and DR and TH mRNA were assayed by real time PCR as previously described 
[20]. Briefly, total RNA was extracted from PBMC by PerfectPure™ RNA Cell & Tissue kit 
(5Prime), and the amount of extracted RNA was estimated by spectrophotometry at 260 nm. 
Total RNA was then reverse transcribed using the High-capacity cDNA Archive Kit 
(Applied Biosystems, Foster City, USA), according to the manufacturer’s instructions. Real-
time PCR was performed with an ABI prism 7000 apparatus (Applied Biosystems) using the 
Assay on demand kits for the genes of interest (Applied Biosystems), according to the 
manufacturer’s instructions. Gene sequence data were obtained from the Reference 
Sequence collection (RefSeq; www.ncbi.nlm.nih.gov/projects/RefSeq). The thermal profile 
for each gene was: stage 1, 2 min at 50°C; stage 2, 10 min at 95°C; stage 3, 40 cycles 
including 15 s at 95°C and 1 min at 60°C. Further details about real-time PCR conditions are 
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shown in Table 1. Linearity of real-time PCR assays were tested by constructing standard 
curves by use of serial 2-fold dilutions of a standard calibrator cDNA and regression 
coefficients (r2) were always >0.900 (data not shown). Relative expression was determined 
by normalization to 18S rRNA (housekeeping gene) by means of AB Prism 7000 SDS 
software™. Supporting information (S1 Fig) shows HKG levels (expressed as Ct) for the 
different genes, and also the comparison between the two groups of subjects. No difference 
is statistically significant and the range of the individual values is very narrow (about one 
cycle) and clearly superimposed between groups and throughout genes. In addition, HKG 
minor variations are not influential and likely due to small variations in the amount of cDNA 
pipetted for the PCR analysis. Gene expression levels in a given sample were represented as 
2-Ct where Ct = [Ct (gene) – Ct (18S rRNA)]. The ratio (R) was calculated for DR and TH 
mRNA expression between individuals with and without CO. R<0.5 was conventionally 
considered as under expression and R>2.0 as overexpression. 
All the parameters were assessed in 30 (17 with and 13 without CO) individuals, except 
leptin and CD11b, assessed in 21 (11 with and 10 without CO) and 13 (8 with and 5 without 
CO), respectively.  
 
Statistical Analysis 
The modified Kolmogorov-Smirnov test with the correction of Lilliefors was used to 
evaluate the fit of the data to a normal distribution. Variables were summarized using 
relative and absolute frequencies or means±standard error of the mean (SEM), as 
appropriate. Non-normally distributed data were summarized as median, 25th and 75th 
percentiles. To compare the quantitative independent variables, we used bivariate ANOVA 
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or Mann-Whitney tests for normally and non-normally distributed data, respectively. The 
Pearson Chi-Square test was used to compare qualitative independent variables. Correlations 
were assessed by non-parametric Spearman rank analysis. Only those correlations with 
significance lower or equal to 0.01 were considered. The strength of association between 
variables was estimated by odds ratio (OR) and their respective 95% confidence interval 
(CI) using multiple logistic regression. Variables that in the univariate analysis showed 
statistical significance below 10% (p <0.10) were included in the logistic regression model.  
Data analysis was performed using the SPSS version 22.0 (SPSS, Chicago, IL, USA).  
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Results 
 
Characteristics of the study population 
In this cohort of blood donors, the prevalence of central obesity was 57.7%, and the mean 
BMI was 30±1.5 and 24±0.7 kg.m-2, respectively in individuals with and without CO (Table 
2). There were no differences between subjects without and with CO, with the exception of 
plasma leptin which was higher in CO. 
Plasma CA levels were similar between WC established groups, but in CO AD correlated 
with leptin (r = 0.860; P = 0.001). In the whole population, total monocytes were 446±31 
cells/μL and no differences were noticed between subjects with and without CO (415±34 vs 
487±55, respectively; p = 0.253). 
Total monocyte count as well as CD16+ and CD16- monocytes were not different between 
subjects with and without CO (Tables 2 and 3) however, in comparison to monocytes from 
subjects without CO, cells from subjects with CO showed lower SSC, CD14, CD11b, and 
CD36 ratios (Table 3), defining a higher inflammatory phenotype for pro-inflammatory 
monocytes. 
 
Expression of DR and TH in PBMC 
Compared to PBMC from subjects without CO, cells from individuals with CO expressed 
lower D1-like DR D5 (R = 0.29) and D2-like DR D2 (R = 0.13) and D4 (R = 0.47), as well 
as lower TH mRNA (R = 0.58) (Fig 1). In centrally obese individuals, the comparison 
between obese and non-obese BMI defined did not show differences in mRNA levels of TH 
and DR in PBMC (S1 Table). 
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Boxes indicate medians with 25th–75th percentiles and whiskers indicate minimum and 
maximum values. Mann-Whitney test used for comparison between the two groups. 
Abbreviations: Tyrosine hydroxylase (TH), Central Obesity (CO), DRD1 dopaminergic 
receptor type1, DRD2 dopaminergic receptor type 2, DRD3 dopaminergic receptor type 3, 
DRD4 dopaminergic receptor type 4, DRD5 dopaminergic receptor type 5, Significant 
differences are indicated (P value). 
 
Correlation between DR and TH mRNA expression in PBMC and anthropometric, 
metabolic/endocrine and inflammatory markers 
As shown in Table 4, in the whole cohort, the expression of DR D2 and DR D5 mRNA in 
PBMC was negatively correlated with weight, BMI, WC and leptin levels, and positively 
correlated with CD11b ratio in monocytes. Moreover, DR D4 mRNA was negatively 
correlated with HbA1c and TH mRNA was correlated with lower WC and leptin levels. 
In the model of CO, the logistic regression analysis showed a lower association for the 
development of central obesity for DR D2 mRNA expression ≥0.0000000455 (odds ratio 
[OR] 0.018 confidence interval [CI] 95% 0002–0.195). 
All data are included in the supporting information (S1 Dataset). 
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Discussion 
 
This is the first work studying the expression of DR and TH in peripheral immune cells in 
obesity. Our findings show that CO is associated with inflammation, as shown by higher 
plasma levels of leptin and a more inflammatory pattern of non-classical monocytes, and 
that in CO PBMC exhibit a distinct pattern of DR and TH expression. In particular: (i) 
PBMC from subjects with CO show a reduction of the expression of DR D2, DR D4 and DR 
D5 as well as lower levels of TH mRNA in comparison to cells from the non-obese group; 
(ii) DR D2 and DR D5 expression in PBMC strongly correlates with lower weight, BMI and 
WC, lower plasma levels of leptin and with a lower inflammatory pattern, while DR D4 
mRNA correlates with less HbA1c and TH mRNA correlates with lower WC and leptin 
levels; (iii) the expression of DR D2 may have a protective role against the presence of CO. 
 The relationship between DA and obesity has been subject of extensive research in the 
nervous system (14-16, 21). Scientific evidence has established an association between 
obesity and hyposensitivity of dopaminergic systems, both within the CNS (22) and in 
peripheral tissues (23). While DA brain functions are well known, its peripheral role is an 
emerging subject of study. An association between the intake of a high fat diet and 
alterations in brain DA levels (24, 25) has been already described, and Wang et al. (2001) 
reported that in obese DR D2 availability correlated negatively with BMI (22). 
Till now, knowledge about the role of DA in peripheral tissues during obesity has been 
limited to its influence on pancreatic β cells regulating insulin release (26) and to the 
modulation of insulin effects on adipocytes (21). Indeed, Borcherding et al (2011) suggested 
a regulatory role of peripheral DA in adipose tissue functions as human adipocytes cell lines 
express DR (27).  
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In our study, we found decreased DR D2, D4 and D5 as well as TH mRNA levels in PBMC 
from subjects with CO. Decreased expression of DR D2 in PBMC has been already reported 
in other inflammatory immune mediated diseases such as Crohn’s disease (28) and systemic 
lupus erythematosus (SLE) (29). Indeed, administration of DR D2 agonists reduced disease 
activity in patients with rheumatoid arthritis (30, 31) and decreased serum immunoglobulin 
and anti-DNA antibody levels in SLE patients (30). Single-nucleotide polymorphisms of DR 
D2, associated to lower expression and function, increase inflammation in human renal 
proximal tubule cells (32). In human lymphocytes, DR D2 agonists increase the secretion of 
anti-inflammatory cytokines (33). As regards DR D5, their reduction in PBMC has been 
previously reported in patients suffering from multiple sclerosis (34, 35), an immune-
mediated inflammatory disease in which DR D5 expression in PBMC has been also 
suggested to predict the therapeutic response to immunomodulating treatment with 
interferon- (35). 
In our study, PBMC expression of DR D2 and D5 (and to a lesser extent also of D4 and TH) 
were shown to be associated with lower weight, with better metabolic/endocrine parameters 
and with a less inflammatory pattern. Moreover, logistic regression analysis suggests that 
DR D2 expression has a protective role for the existence of CO.  
The correlations between the expression of DR and TH in PBMC and more favorable 
metabolic/endocrine and inflammatory parameters suggest a possible role for dopaminergic 
pathways in the crosstalk between immunity and metabolism. Indeed, adipose tissue express 
DR and DA regulates adipose tissue functions (27). So far, DA has been shown to have an 
inhibitory effect on leptin release from human adipocytes through D1-like DR receptors (27) 
and to modify the secretion of insulin in peripheral tissues (21). Yu et al. (2014) described a 
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negative effect through DR D4 activation on insulin action via decreasing insulin receptor 
expression (36). Peripheral blockade of DR could therefore result in increased insulin 
release and sensitivity, thus promoting adipogenesis, weight gain, insulin resistance, and 
ultimately type 2 diabetes (21), adverse metabolic effects also described for neuroleptics 
(37). DA inhibitory effects on the release and action of insulin may explain the inverse 
correlation between DR D4 expression in PBMC and HbA1c plasma levels found in the 
present work. The inhibitory effect of DA on leptin release mediated by DR is in agreement 
with the relationship found between DR expression and leptin, considering PBMC as early 
sensors for metabolic dysfunction. The major sources of DA in peripheral blood are 
neuronal fibers, adrenal medulla and neuroendocrine cells (38), and although the type of 
food ingested could affect blood DA levels (21, 39-41) and putatively the expression and 
function of DR, in our study blood samples were collected in a fasted state.   
Our work has some limitations. First, we did not analyze DR at protein level. Even though, 
Araki et al (2007) showed that DR mRNA and membrane-associated protein changes 
correspond with each other; moreover, the same authors demonstrated that DR mRNA 
expression or receptor protein are valid surrogates for receptor function (42) and our group 
previously showed that DR responsiveness in human lymphocytes is better predicted by 
mRNA rather than membrane receptor expression (12). 
Secondly, we do not know if the different pattern of DR and TH expression on PBMC 
associated with CO is a cause or consequence of inflammatory obesity. This open question 
should be answered prospectively with further studies addressing the effect of weight loss on 
DR expression in peripheral immune cells. Finally, DR expression was assessed in PBMC as 
a whole, and future studies should address the possible differential expression on distinct 
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mononuclear cell subsets (e.g. lymphocytes vs monocytes, T helper (TH) 1 vs Th2, 
regulatory T cells vs Th17). 
Conclusions 
To our knowledge, this is the first work studying the expression of DR and TH in peripheral 
immune cells in obesity. CO is associated with under expression of DR D2, DR D4 and DR 
D5, lower levels of TH mRNA in PBMC and with a higher innate inflammatory pattern. The 
expression of DR correlated with lower weight, with better metabolic profile and lower 
inflammatory pattern. The expression of DR D2 showed a protective role for the 
development of CO. Results thus indicate that CO is associated with peripheral 
inflammation and downregulation of dopaminergic pathways in PBMC, and warrant further 
research to establish whether DR expressed on immune cells could represent 
pharmacological targets in obesity for better metabolic outcome. 
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Table 1 Real-Time PCR gene expression. Data are from RefSeq - NCBI Reference 
Sequence Database (http://www.ncbi.nlm.nih.gov/refseq/) 
Gene UniGene ID 
Interrogated 
Sequence 
Translated 
Protein 
Exon 
Boundary 
Assay 
Location 
Amplicon 
Length 
TH Hs.435609 NM_199292.2 NP_954986.2 3-4 424-422 63 
DRD1 Hs.2624 NM_000794.3 NP_000785.1 1-2 462-1620 110 
DRD2 Hs.73893 NM_000795.3 NP_000786.1 2-3 524 64 
DRD3 Hs.121478 NM_033663.3 NP_387512.3 3-4 809-725 73 
DRD4 Hs.99922 NM_000797.3 NP_000788.2 1-2 285-283 99 
DRD5 Hs.380681 NM_000798.4 NP_000789.1 1-1 1092-744 88 
18SrRNA X03205.1 N/A N/A N/A N/A 187 
Abbreviations:TH tyrosine hydroxylase, DRD1 dopaminergic receptor type1, DRD2 dopaminergic receptor type 
2, DRD3 dopaminergic receptor type 3, DRD4 dopaminergic receptor type 4, DRD5  dopaminergic receptor type 
5. 
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Table 2 Characteristics of overall the participants (n=30) and comparison between groups defined by Waist Circumference 
 overall Central Obesity  
Parameter Reference values 
(range) 
mean± SEM/ F df No CO (N=13) CO (N=17) P 
Age (years)  41±2 0.795 1, 28 39±3 42±2 0.380 
Weight (Kg)   76±3 3.302 1, 28 70±2 80±4 0.080 
Height (m)  1.67±0.02 5.780 1, 28 1.71±0.01 1.64±0.02 0.023 
BMI (kgm-2)  27.2±1.0 10.448 1, 28 24±0.7 30±1.5 0.003 
WC (m)  0.95±0.03 13.492 1, 28 0.86±0.02 1.02±0.04 0.001 
SBP (mmHg) <130 134±3 0.120 1, 28 133±4 135±5 0.732 
DBP (mmHg) <85 79±2 0.362 1, 28 77±2 80±3 0.552 
Glycemia (mg/dL) 70 - 105 85±1 0.200 1, 28 86±1 84±2 0.659 
HgA1c (%) 3.8 - 5.6 5.2±0.06 2.070 1, 28 5.1±0.08 5.3±0.07 0.161 
TC (mg/dL) 0 - 200 188±7 0.807 1, 28 181±10 193±9 0.377 
LDL-C (mg/dL) 0 - 130 117±6 0.084 1, 28 115±9 118±8 0.774 
HDL-C (mg/dL) 35 - 55 51±3 0.080 1, 28 50±4 52±4 0.780 
VLDL-C (mg/dL) 3 - 56 20±2 2.901 1, 28 16±2 23±3 0.100 
TAG (mg/dL) 40 - 160 99±10 2.855 1, 28 80±9 113±16 0.102 
hsCRP (mg/L) < 1.0 low risk 
1.0 <3.0 intermediate 
risk 
>3.0 high risk 
1.575 (0.571-
3.020) 
- - 
0.801 (0.571-
2.090) 
1.840(0.672-
3.560) 
0.408 
NA (pmol/L) 709 - 4019 879±131 0.444 1, 28 778±185 956±185 0.511 
AD (pmol/L) <328 167±17 0.172 1, 28 175±31 160±18 0.682 
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Cortisol (g/dL) 6.2 – 19.4 15±0.8 0.439 1, 28 16±1 15±1 0.513 
Leptin (ng/mL) 2.0 – 5.6 0.9±0.3 6.779 1, 19 0.138±0.047 1.626±0.542 0.017 
Leucocytes (cells/L) 4500 - 13000 6403±280 1.823 1, 28 5977±483 6729±319 0.188 
Monocytes (cells/L) 400 - 500 446±31 1.361 1, 28 487±55 415±34 0.253 
Lymphocytes (cells/L) 1000 - 4800 1951±96 3.729 1, 28 1748±123 2106±131 0.064 
Abbreviations: BMI Body Mass Index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycosylated hemoglobin, TC total cholesterol, 
LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein-cholesterol, VLDL-C very low-density lipoprotein-cholesterol, TAG triacylglycerol, hsCRP high-
sensitivity C reactive protein; NA, noradrenaline; AD, adrenaline; F Snedcor’s distribution; df default freedom; p level of significance. Data are presented as mean  standard error 
of the mean (SEM). Differences between groups were analyzed by ANOVA. Data presented as median, 25th and 75th percentiles and statistical analysis performed with Mann- 
Whitney U test for the differences between the 2 groups.  
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Table 3 Immunophenotypic characteristics of CD16+ and CD16- monocytes in overall of the study 
participants and categorized by CO 
 overall without CO With CO  
 Mean±SEM 
Ratio 
CD16+/CD16- 
p Mean±SEM 
Ratio 
CD16+/CD16- 
Mean±SEM 
Ratio 
CD16+/CD16 
p- 
cells/L 
CD16+ 54±12 
0.14±0.02 <0.001 
57±21 
0.12±0.03 
53±13 
0.15±0.03 ns 
CD16- 392±25 430±43 362±28 
cells% 
CD16+ 11.4±1.4 
0.14±0.02 <0.001 
10±2 
0.13±0.03 
12±2 
0.15±0.03 ns 
CD16- 88.6±1.4 90±2 88±2 
FSC 
CD16+ 557±11 
1±0.005 ns 
546±18 
1.00±0.01 
560±13 
1.00±0.01 ns 
CD16- 558±11 548±17 565±13 
SSC 
CD16+ 418±10 
0.86±0.01 <0.001 
435±17 
0.89±0.02 
405±11 
0.84±0.01 0.022 
CD16- 486±8 488±13 483±10 
CD14 
CD16+ 875±109 
0.41±0.03 <0.001 
893±163 
0.51±0.05 
860±151 
0.34±0.03 0.009 
CD16- 2340±322 1874±353 2561±476 
CD36 
CD16+ 307±30 
0.43±0.03 <0.001 
332±59 
0.51±0.05 
282±28 
0.38±0.03 0.023 
CD16- 733±43 671±78 781±45 
CD11b 
CD16+ 106±25 
0.49±0.05 0.050 
90±35 
0.64±0.05 
115±35 
0.40±0.06 0.015 
CD16- 304±112 143±54 405±174 
Abbreviations: CO central obesity; FSC forward scatter; SSC side scatter; ns not significant. Values of CD14, CD36 and CD11b 
expressed as fluorescence arbitrary units (AU). Data are presented as mean  standard error of the mean (SEM). Differences between 
groups analyzed by ANOVA p, level of significance; p significance between CD16+ and CD16- monocytes subsets. 
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Table 4 Correlations between dopaminergic receptors and tyrosine hydroxylase expression 
and anthropometric, metabolic/endocrine and inflammatory parameters 
 TH DRD2 DRD3 DRD4 DRD5 
r P r P r P r P r P 
Weight ns -0.502 0.005 ns ns -0.483 0.007 
BMI ns -0.577 0.001 ns ns -0.557 0.001 
WC -0.529 0.003 -0.681 <0.001 ns ns -0.621 <0.001 
HbA1c ns ns ns -0.605 <0.001 ns 
Leptin -0.555 0.009 -0.739 <0.001 ns ns -0.618 0.003 
Ratio 
CD11b 
ns 0.927 <0.001 ns ns 0.748 0.003 
Abbreviations:TH tyrosine hydroxylase, DRD2 dopaminergic receptor type 2, DRD3 dopaminergic receptor 
type 3, DRD4  dopaminergic receptor type 4, DRD5 dopaminergic receptor type 5, BMI, Body mass index; WC 
waist circumference; HbA1c glycosylated hemoglobin; Ratio CD11b, ratio between the expression of 
CD11b in CD16+ monocytes and the expression of CD11b in CD16- monocytes and the median 
fluorescence intensity of CD11b was assessed in each subset and expressed as fluorescence arbitrary units; r 
correlation coefficients, calculated by Spearman’s rho test; P level of significance; ns not significant if 
P>0.01. 
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Chapter 5: Paper 4 (Letter to Editor)- The effect of blood 
donor characteristics on transfusion outcomes: should obesity 
be assessed in future clinical trials?  
 
5.1 Preface to Paper 4 
Our results showed differences in peripheral immune cells concerning catecholaminergic 
receptors and tyrosine hydroxylase transcripts and phenotype between blood donors with 
and without inflammatory obesity. We also found different plasma levels of molecules with 
an immumodulating role such lipids and leptin. Taking into account the association between 
blood donor characteristics (BDC) and transfusion outcomes, we hypothesize that obesity is 
one characteristic that may affect transfusion recipient outcomes. Moreover, we performed a 
preliminary study in 63 BD to investigate the associations between BMI, WC, leptin and 
high-sensitivity C-reactive protein plasma levels as donor characteristics and red blood cells 
transfusion recipient mortality (data not published). We discuss the clinical and biological 
rationale for this hypothesis.  
 
5.2 Paper 4 
Leite F, Leite Â, Ribeiro L. The effect of blood donor characteristics on transfusion 
outcomes: should obesity be assessed in future clinical trials? JAMA Intern Med. 
2017;177(4):599. doi:10.1001/jamainternmed.2017.0236. 
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The effect of blood donor characteristics on transfusion outcomes: should obesity be 
assessed in future clinical trials? 
 
To the Editor: The work of Chassé and colleagues1 in a recent issue of JAMA Internal 
Medicine reported that blood donor (BD) characteristics may affect red blood cell (RBC) 
transfusion outcomes and describe a higher risk of death for recipients of RBC transfusions 
from young donors and female donors independently of recipient age, sex, and 
comorbidities. The authors discuss these results mentioning the healthy donor phenomenon 
and the blood composition in female gender, not ruling out unknown 
biological/environmental factors.  
Considered healthier than the general population, BD present cardiovascular risk factors, 
particularly, obesity. The health consequences for recipients of blood transfusion or bone 
marrow transplantation from donors with obesity are unrevealed notwithstanding being 
expected. The clinical and biological rationale for this hypothesis is based on scientific 
evidences widely accepted: i) obesity is an inflammatory disease and “inflamed donors”, 
apart from showing altered immune cells at genomic, phenotype and function levels, also 
have in circulation immunoregulators such as leptin, lipids, extracellular vesicles, 
microRNAs signalling molecules implicated in adaptive and innate immune activation with 
a role in obesity and cardiovascular comorbidities2; ii) the signalling of leptin, a 
proinflammatory cytokine primarily produced by adipocytes proportionally to adiposity and 
present in higher levels in women, is associated with the occurrence, progression and 
prognosis of hematologic malignancies3; iii) it has been described low CD34+ cells harvest 
in overweight or obese mothers, candidates for stem cell donation of umbilical cord blood 
units, and in new-borns weighing above the average4. Although the composition of immune 
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cells in the allograft may affect the clinical outcomes of patients, the impact of donor 
weight/BMI on CD34+ cells remains controversial. Central obesity, a more sensitive obesity 
measurement for inflammation than body mass index (BMI), could, partially, explain the 
contradictory results in the association between BMI/weight and immune cell composition 
of allograft. Moreover, even leukodepleted, RBC have some residual leukocytes with stem 
cell function.  
A population of BD with CO prevalence of 57.7%, showed higher inflammatory phenotype 
pattern of monocytes in CO compared with their counterpart5. The existence of “inflamed” 
donors is even more important when a significant part of the recipients is 
immunocompromised. Future clinical trials with vein-to-vein methodology are needed to 
evaluate if inflammatory obesity matters as a characteristic of donor on clinical outcomes of 
recipients of blood transfusion/hematopoietic stem cell transplantation. 
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Chapter 6: Discussion 
 
6.1. Summary of Findings 
In this thesis project, our first drive was to find early markers for inflammatory obesity in 
order to precociously intervene therapeutically and contribute for prevention of 
comorbidities obesity-associated that threaten human life span. 
Considered healthier than the general population due to donation eligibility requirements, 
blood donors were deliberately chosen as a low CV risk subjects. In our sample, the central 
adiposity measure, contrary to general, was sensitive to metabolic risk factors and to a more 
pro-inflammatory pattern of CD16+ monocytes (reflecting a higher activation of the innate 
immune system) with no expansion of this monocyte subset. In CO, lower CD14 expression 
on CD16+ cells as well lower cellular complexity, in comparison to their counterpart, 
describe a more mature monocyte population claimed with higher capacity of migration and 
recruitment into the adipose tissue (AT).  
According to our results, studies in human chronic low-grade pathologies associated with 
inflammation did not find changes in CD16+monocytes counting (1-3). Several works 
aimed at functional characterization of the monocyte subsets have been undertaken by 
different research groups (4-7) with contradictory results. This fact can be explained by lack 
of a standardized gating strategy for immunophenotyping by flow cytometry and by the use 
of different protocols to isolate purified monocytes (8). We performed the experiments in 
whole blood, avoiding purification protocols that can contribute to significant changes in 
receptor expression. 
Multiple linear regression analysis was performed to identify the variables that best predict 
CO after controlling for potential confounders. A model, including leptin, ratio CD14, 
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VLDL-C, was found to be predictor of more than one third of CO. It is well-established that 
leptin promotes activation and proliferation of circulating monocytes, their differentiation 
into macrophages and inducing the secretion of proinflammatory cytokines  (such as IL-1, 
TNF or IL-6 in synergy with lipopolysaccharide (LPS)), stimulates the oxidative burst and 
can enhance chemotactic responses by acting as a chemoattractant in monocyte and/or 
macrophages. Despite its immune regulatory role on human monocytes (9), leptin could not 
be the only factor explaining the CD16+ inflammatory pattern found in centrally obese, as 
its levels were also elevated in general obese. On the other hand, centrally obese individuals 
showed significantly higher levels of TAG, TC and VLDL-C comparing to non-centrally 
obese and these differences were not noticed between BMI groups. Circulating lipids may 
modify immune cells function (10, 11) being responsible for the production of intercellular 
signaling molecules. The hepatic overproduction of VLDL seems to be the primary and 
crucial defect in obesity (12). VLDL particles, exposed to lipoprotein lipase in the peripheral 
circulation which hydrolyses the triglyceride in VLDL particles, generate FFAs. Saturated 
FFAs, originated from hypertrophied AT, constitute a chemoattractant factor with a key role 
in AT monocytes recruitment. These lipids may directly induce inflammatory pathways in 
adipocytes through the activation of cell receptors producing inflammatory cytokines. Thus, 
in centrally obese, dyslipidemia, resulting from metabolic and visceral AT dysfunction, and 
leptin may contribute to a more inflammatory phenotype of circulatory CD16+, an early 
event of inflammatory obesity. Our work suggests that in subclinical inflammatory obesity, 
dyslipidemia and leptin could induce monocytes maturation process rather than an 
independent arise of CD16+ monocytes.  
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CD16+ monocytes seem to reside in a marginal pool mobilized by a catecholamine-
dependent pathway (13). In CO, but not in BMI-defined obese, AD is associated with the 
expansion of CD16+ monocyte subset, but with a less inflammatory phenotype.  
In line with the results of Thorand et al. (14), our study describes a stronger association of 
inflammation and obesity in female. Indeed, women showed higher levels of leptin, that, as 
previously mentioned, is an important immunomodulator usually associated to inflammatory 
immune responses (9). Moreover, CA behave differently by gender (14). AD plasma levels 
were associated with a lower inflammatory CD16+monocytes phenotype in women and with 
a higher level of inflammation in man. In opposite, NA was associated with a higher 
inflammatory phenotype only in female. These findings could be explained by higher 
percentage of adiposity in female and differences in endogenous hormones.  
In obesity, the identity of immunoreceptors sensing metabolic-stress signals and triggering 
inflammation is largely unknown. PBMC, our model of immunity, are modulated by CA, 
being able to produce and utilize DA, NA and AD as mediators acting through activation of 
AR and DR expressed in immune cells (15). Our first work suggested that CA (AD and NA) 
have an immunomodulatory role in obesity. In the second part of our work, we hypothesized 
the existence of a different pattern of the expression of catecholaminergic receptors in 
PBMC in inflammatory obesity and their association with a different metabolic profile and 
inflammatory sate. 
The preliminary results obtained through a pilot study considering PBMC expression of all 
the 9 AR (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2 and β3) in a subgroup of subjects with and 
without CO revealed no differences between groups except for β2AR mRNA levels. The 
expression of β2AR in the subjects with CO was less than half in comparison to that in 
individuals without CO. This finding led us to study β2AR expression in whole population 
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showing that β2AR in PBMC were under expressed in CO individuals in comparison to non-
CO subjects. The multiple logistic regression analysis showed a lower and higher 
association, respectively for β2AR expression (≥2x10-6) and female gender for the 
occurrence of CO.  
β2AR transcripts correlated with HDL-C and inversely with TAG, VLDL-C and leptin 
plasma levels. AD and NA plasma levels were associated with dyslipidemia. As stated 
before, dyslipidemia in obesity is characterized by an increase of FFAs, ligands for TLR4. 
The activation of TLR4 induces downstream signaling of the nuclear factor-kappa B (NF-
kB) and consequently the expression of pro-inflammatory cytokines with down regulation of 
β2AR turning the immune cells responsiveness (10). Our results are in line with the 
influence of cellular lipid homeostasis on the levels, phenotype and function of immune cells 
(16) since in centrally obese HDL-C levels were positively related with β2AR mRNA and 
inversely with AD. On the other hand, NA, an independent factor for the development of 
metabolic syndrome (17), correlated not only with TC and LDL-C, but also with the number 
of “pro-inflammatory monocytes” and hsCRP, findings that corroborate an inflammatory 
role for CA in inflammation obesity-associated (18). β2AR expression in PBMC might have 
a protective role for the presence of CO being associated with a better metabolic lipid 
profile. 
A possible explanation for PBMC β2AR under expression in CO could be desensitization 
and down-regulation resultant from the action of circulating or endogenously produced CA, 
leptin and other cytokines and lipids. β2ARs are the most expressed ARs on immune cells 
and considered the main mediators of CA immune effects; their activation on human 
monocytes is usually antiinflammatory and immunosuppressive (19, 20).  
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Our work supports the immunomodulatory role of β2AR in central obesity since β2AR 
mRNA inversely correlated with the plasma level of leptin, a pro-inflammatory adipokine 
(9) and leptinemia correlated with hsCRP levels and with a more inflammatory phenotype of 
monocytes in the high hsCRP cardiovascular risk group. Leptin receptors, found in 
monocytes and lymphocytes (21) mediate the production of proinflammatory cytokines by 
these cells (22). In centrally obese, leptin plasma values were also correlated with the 
hsCRP, also synthesized by adipocytes (23) and described as able to affect β2AR function 
(24). 
Further studies are needed to elucidate whether the altered pattern of β2AR and monocytes 
observed in an early phase of CO is a cause or consequence of inflammatory obesity. The 
lower expression of β2AR in PBMC of CO individuals is in accordance with the 
inflammatory pattern of visceral obesity and as a result of the effects of leptin and lipids on 
immune cells. Our findings are in line with a decreased number of β2AR in PBMC from 
patients with inflammatory immune mediated diseases (25-29) and with critical heart 
disease, a chronic low-intensity inflammation condition, also associated with reduced β-AR 
on lymphocytes due to a non-regulated increased release of proinflammatory cytokines (29). 
While several lines of evidence support the involvement of DA in obesity through its role in 
the central nervous system no information existed regarding dopaminergic pathways in 
peripheral immune cells of obese subjects. We therefore decided, in a third experimental 
work, to study the expression of DR and TH, the rate-limiting enzyme in the synthesis of 
DA, in PBMC. 
PBMC from subjects with CO showed a reduction of the expression of DR D2, DR D4 and 
DR D5 as well as lower levels of TH mRNA in comparison to cells from the non-obese 
group. Decreased expression of DR D2 and/or DR D5 in PBMC has been already reported 
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in other inflammatory immune mediated diseases (30, 31). In human lymphocytes, DR D2 
agonists increase the secretion of anti-inflammatory cytokines (32). 
DR D2 and DR D5 expression in PBMC strongly correlates with lower weight, BMI and 
WC, lower plasma levels of leptin and with a lower inflammatory pattern, while DR D4 
mRNA correlates with less HbA1c and TH mRNA correlates with lower WC and leptin 
levels.  
That is, PBMC expression of DR D2 and D5 (and to a lesser extent also of D4 and TH) were 
shown to be associated with lower weight, with better metabolic/endocrine parameters and 
with a less inflammatory pattern. Moreover, logistic regression analysis suggests that DR D2 
expression has a protective role for the existence of CO. 
The correlations found between the expression of DR and TH in PBMC and more favorable 
metabolic/endocrine and inflammatory parameters suggest a possible role for dopaminergic 
pathways in the crosstalk between immunity and metabolism. Indeed, AT express DR and 
DA regulates AT functions (33). So far, DA has been shown to have an inhibitory effect on 
leptin release from human adipocytes through D1-like DR receptors (33) and to modify the 
secretion of insulin in peripheral tissues (34). Peripheral blockade of DR could therefore 
result in increased insulin release, thus promoting adipogenesis, weight gain, insulin 
resistance, and ultimately T2D (34), adverse metabolic effects also described for 
neuroleptics (35). DA inhibitory effects on the release and action of insulin may explain the 
inverse correlation between DR D4 expression in PBMC and HbA1c plasma levels. The 
inhibitory effect of DA on leptin release mediated by DR is in agreement with the 
relationship found between DR expression and leptin, considering PBMC as early sensors 
for metabolic dysfunction. 
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The results of this experimental work indicate that CO, associated with peripheral 
inflammation and downregulation of dopaminergic pathways in PBMC, warrant further 
research to establish whether DR expressed on immune cells could represent 
pharmacological targets in obesity for better metabolic outcome. We have commented that 
dopaminergic pathways could represent a promising approach clarifying the biological basis 
of obesity, claimed by Hotamisligil (36, 37), regulating the immune response in metabolic 
disease clusters. Targeting DA might allow simultaneously target obesity and inflammation.  
It has been approached the issue of transfusion outcomes of blood recipients, already 
immunocompromised, from “inflamed blood donors”. Since blood donor’s characteristics 
have implications on transfusion outcomes (38) and we found differences between centrally 
obese and non-centrally obese considering immune cells characteristics and circulating 
immunomodulators molecules, we questioned whether obesity should be included in future 
clinical trials. The health consequences for recipients of blood transfusions or bone marrow 
transplantation from donors with obesity are unrevealed notwithstanding being expected. 
The clinical and biological rationale for this hypothesis is based on scientific evidences 
widely accepted: (i) obesity is an inflammatory disease and “inflamed donors,” apart from 
showing altered immune cells at genomic, phenotype, and function levels, also have in 
circulation immunoregulators such as leptin, lipids, extracellular vesicles, microRNAs 
signaling molecules implicated in adaptive and innate immune activation with a role in 
obesity and cardiovascular comorbidities (39); (ii) the signaling of leptin, a proinflammatory 
cytokine primarily produced by adipocytes proportionally to adiposity and present in higher 
levels in women, is associated with the occurrence, progression, and prognosis of 
hematologic malignancies (40); (iii) low CD34+ cell count has been described in blood 
harvested from overweight or obese mothers, candidates for stem cell donation of umbilical 
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cord blood units, and in newborns weighing above average (41); (iv) although the 
composition of immune cells in the allograft may affect the clinical outcomes of patients, the 
impact of donor weight and/or BMI on CD34+ cells remains controversial. CO, a more 
sensitive obesity measurement for inflammation than BMI, could, partially, explain the 
contradictory results in the association between BMI /weight and immune cell composition 
of allograft. Moreover, even leukodepleted, red blood cells have some residual leukocytes 
with stem cell function. Inflammatory obesity, concerning the effect of donor’s 
characteristics on transfusion outcomes, should be considered in blood donor’s selection 
process. If vein-to-vein database will be able to be collected and confirms this hypothesis, it 
is expectable to have consequences in Transfusion Medicine policies concerning 
effectiveness and safety issues.  
 
6.2 Potential impact  
This PhD thesis significantly contributes to the discussion on two major public issues. The 
findings of a predictor model and the protective role of β2AR and DR D2 expression in 
peripheral immune cells for inflammatory obesity are expected to impact, firstly on early 
diagnosis with implementation of WC measurement at primary care settings to define 
inflammatory obesity, and secondly, on therapeutic interventions in inflammation obesity-
associated. 
2AR agonists are currently used as bronchodilating agents in asthma, however the relative 
contribution of any eventual immunomodulating activity to their overall therapeutic effects 
remains to be established. Hence, evaluation of these drugs as potential antiinflammatory 
drugs is strongly warranted. 
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Evidence also suggests the opportunity to apply a pharmacogenetics approach to better 
understand adrenergic modulation of the immune response and in particular of innate 
immunity. 2AR has mutant forms (42), nonetheless, the present knowledge about the 
adrenergic modulation of innate immunity supports relevant therapeutic applications. 
Moreover, as adrenergic pathways also provide a link between stressful events and chronic 
inflammatory disease such as obesity and atherosclerosis (43), investigating neuroimmune 
adrenergic mechanisms will likely provide several opportunities to repurpose the wide array 
of sympathoadrenergic agents currently used in medical therapy for various non-immune 
indications for novel and previously unanticipated indications.  
 
6.3 Limitations 
The expression of adrenergic and dopaminergic receptors was evaluated in PBMC and in 
future studies it would be valuable to investigate possible differential expression on distinct 
mononuclear cell subsets (e.g. lymphocytes vs monocytes, T helper (TH) 1 vs Th2, 
regulatory T cells vs Th17). Furthermore, we studied AR and DR transcripts and it would be 
relevant to also measure their protein levels. Nonetheless, Guereshi et al. (44) found that 
β2AR mRNA levels were higher in naıve T cells than in Treg cells and protein expression 
confirmed the results for β2AR transcripts. Studies examining the distribution of cells 
expressing DR mRNA and DR binding sites have shown a good agreement between 
distributions (45). It has been postulated that DA receptors in peripheral blood lymphocytes 
reflect the status of homologous brain receptors (46, 47). In addition, DR mRNA and 
membrane-associated protein changes correspond with each other considering DR mRNA 
expression or receptor protein valid surrogates for receptor function (48). Our group also 
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showed in human lymphocytes that DR responsiveness is better predicted by mRNA rather 
than membrane receptor expression (49). 
Secondly, we could not answer whether the different pattern of AR, DR and TH expression 
on PBMC associated with CO is a cause or consequence of inflammatory obesity. This open 
question should be answered prospectively with further studies addressing the effect of 
weight loss on AR and DR expression in peripheral immune cells.  
 
6.4 Conclusions  
This thesis has the novelty of identification and prediction of subclinical inflammatory 
obesity. Determination of plasma leptin and VLDL-C levels and CD14 expression in 
monocytes subsets predict CO in more than 33%. The study herein described supports in 
subclinical inflammatory obesity a process of monocytes maturation rather than an 
independent arise of CD16+ cells induced by dyslipidemia and leptin. Moreover, our work 
provides important insights explaining the stronger association of CO measures with 
cardiometabolic risk in comparison with general obesity assessed by BMI. In addition, the 
implementation of WC, in a public health setting, should be a priority tool for inflammatory 
obesity screening in low cardiovascular risk populations. 
Monocytes of centrally obese sense metabolic/inflammatory circulating factors and these 
signaling molecules induce a maturation process, rather than an expansion, revealed by a 
macrophage-like phenotype with enhanced antigen-presenting capacities, higher endothelial 
affinity, production of proinflammatory cytokines and probable more prone to migrate into 
AT where they could differentiate into macrophages.  
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This is the first work studying the expression of AR, DR and TH in peripheral immune cells 
in obesity, suggesting immunomodulation by CA in this inflammatory condition involving 
the expression of catecholaminergic receptors.  
The expression of DR D2 and β2AR in immune cells may have a protective role for the 
development of CO. In obesity, the increased of inflammatory regulators molecules such 
lipids, leptin and other inflammatory cytokines induce changes at genetic, phenotype and 
consequently at functional levels of peripheral immune cells. This inflammatory systemic 
environment downregulates catecholaminergic receptors in peripheral immune cells, mainly 
those receptors usually associated to anti-inflammatory responses. Both processes perpetuate 
a vicious cycle of inflammatory cell recruitment and secretion of deleterious adipokines and 
FFAs by AT that predispose to metabolic dysfunction.  
The expression of catecholaminergic receptors in PBMC correlated with lower weight, with 
better metabolic profile and lower inflammatory pattern. More studies are needed to know 
whether AR and DR expressed in immune cells could represent pharmacological targets in 
obesity to promote a lower inflammatory state and reverse impaired metabolism.    
 
6.5 Future Directions 
Our findings seem very challenging to further investigate in an early phase of CO the 
phenotypic pattern of circulating monocytes, and its relationship with migratory and 
inflammatory functions.  
Experimental strategies to investigate the immunomodulatory role of endogenous CA can be 
performed interfering with synthesis/degradation, intracellular storage/release/uptake, 
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through effect of receptor blockade and/or use of non-pharmacological approaches, e.g., 
suppression of expression of key proteins by means of gene silencing techniques.  
Further studies are needed to elucidate whether the altered pattern of catecholaminergic 
receptors expression in immune cells observed in an early phase of CO is a cause or 
consequence of inflammatory obesity. It would be interesting to study prospectively the 
effect of weight loss on the expression of the catecholaminergic receptors in immune cells 
whose transcripts were decreased in inflammatory obesity. 
Results thus indicate that CO is associated with peripheral inflammation and downregulation 
of adrenergic and dopaminergic pathways in PBMC, and warrant further research to 
establish whether AR and DR expressed on immune cells could represent pharmacological 
targets in obesity for better metabolic outcome. An important challenge now is to understand 
how AR and DR function on PBMC in inflammatory mechanisms related to obesity before 
we can truly apply this knowledge in a rational manner in clinical conditions.  
In this sense, evaluation of β2-AR and DR D2 agonists as potential anti-inflammatory drugs 
is strongly warranted.  
The results obtained in this thesis raised a very pertinent question regarding the 
characteristics of blood donors which may affect transfusion outcomes in patients. Blood 
donors with CO showed differences in circulating immune cells and signaling molecules 
traducing a more inflammatory state. Immune transfusion reactions may affect recipient 
outcomes and are likely to be related to donor characteristics. Until the present, the main 
exposures that have been studied included donor age and donor sex, with primary outcome 
recipient survival analysis post-red blood cells transfusion. Our work adds grounds for 
future clinical trials to include the assessment of obesity (50), namely central, to 
prospectively study transfusion outcomes covering a clinically representative range of 
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adverse short and long-term events after transfusion (mortality, cardiovascular, oncology, 
mortality, infections, renal). Answering the question of donors obesity effects on patients 
outcomes may improve blood recipient´s health and will impact on decision makers in 
transfusion policy. 
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